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Abstract 
The combatting of drug-resistant cancerous cell lines and strains of P. falciparum remain 
major global health problems to date, with hundreds of thousands of related deaths per 
annum. Early identification of solid tumours and infections, as well as the discovery of drugs 
with new mechanisms of action, are paramount in the fight against drug resistance. This 
study investigates the synthesis, characterisation and biological evaluation of new Mn(I) and 
Re(I) tricarbonyl metallodendrimers, in addition to the formation of a new 99mTc complex for 
use in diagnostic imaging. 
Two series of mono- and multimeric picolylamine ligands, based on polyamine scaffolds, 
were prepared. One series of ligands was functionalised with Re(I)- and Mn(I)-tricarbonyl 
moieties, following the [2 + 1] approach, to form a series of cationic complexes. 
Additionally, a second series of neutral bidentate (N,N)-Mn(I) complexes were prepared. The 
ligands and complexes were characterised using a range of spectroscopic and analytical 
techniques, including 1H, 13C{1H}, and 31P{1H} NMR spectroscopy, infrared spectroscopy, 
and mass spectrometry. 
The stability and CO-release properties of the Mn(I) complexes were investigated using 
UV/Vis absorption spectroscopy. A decrease in the MLCT absorption band suggests the 
release of CO. CO-release was confirmed using a monomeric Mn(I) complex as a model with 
the myoglobin assay. 
The in vitro antiproliferative activity of the Re(I) complexes was investigated against three 
cancerous cell lines (A431, DLD-1 and A2780) and one non-tumourigenic cell line (BJ). The 
complexes displayed moderate to good activity, with all IC50 values in the low micromolar 
range. The tetranuclear complex displayed the highest efficacy against the tested cell lines 
(IC50 = 6 – 14 µM). Selectivity towards the cancerous cell lines was observed for the tri- and 
tetranuclear complexes, with higher IC50 values against the BJ cell line. The in vitro 
antiproliferative activity of the Mn(I) complexes was evaluated against two cancerous cell 
lines (A431 and A375). The tetranuclear [2 + 1] Mn(I) complex displayed the best activity 
against both of the tested cell lines. The [2 + 1] complexes displayed higher in vitro activity 
than their bidentate counterparts. 
The complexes were evaluated as in vitro antiplasmodial agents against chloroquine-sensitive 
(NF54) and chloroquine-resistant (K1) strains of P. falciparum. The [2 + 1] Mn(I) complexes 
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displayed enhanced activity over their Re(I) analogues and their bidentate counterparts. The 
tetranuclear [2 + 1] Mn(I) complex displayed the best activity against the K1 strain (IC50 = 
0.99 µM) and the best resistance index (RI = 0.263) of all the tested complexes. Irradiation of 
selected Mn(I) complexes during incubation with the K1 strain resulted in an almost two-fold 
increase in activity of the [2 + 1] Mn(I) complexes, but a decrease in activity of the bidentate 
Mn(I) complexes. 
Formation of the monomeric radiolabelled product was achieved by reacting 
99mTc(bpy)(CO)3 with a monomeric ligand. The product was isolated using preparative 
HPLC, but the retention time did not match that of the Re(I) analogue, likely due to the 
difference in counterion. Radiolabelling of the multimeric ligands was unsuccessful. 
 
  
   P a g e  | xiii 
 
Abbreviations, Symbols and Units 
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Chapter 1      Introduction and Literature Review 
1.1 Carbon Monoxide 
Carbon monoxide (CO) is an odourless, colourless, chemically inert, diatomic gas.1 It is a 
product of combustion of organic material, and is well known for its lethal effect when present 
in high concentrations.1 In 1949 Sjostrand discovered that CO is produced endogenously in 
small quantities in the human body.2 It is now known that small molecules, such as CO, NO 
and H2S, play roles as chemical signalling molecules in mammalian organisms.3-5 
The toxicity of CO to mammals is attributed to the high affinity between the CO molecule and 
haemoglobin (Hb), the iron-containing oxygen-transport protein found in mammals.1, 6 The 
affinity between CO and haemoglobin is approximately 220 times stronger than the affinity 
between molecular oxygen and haemoglobin.6 Under normal atmospheric conditions, the 
concentration of oxygen is much higher than that of CO, so oxygen is preferentially bound to 
haemoglobin. However, when the concentration of CO increases, haemoglobin binds the CO, 
forming carboxy-haemoglobin (Hb-CO). Due to the high affinity between CO and 
haemoglobin, CO dissociation from Hb-CO takes a relatively long time, and the haemoglobin 
is not available to transport oxygen in the blood. This can lead to tissue hypoxia and, at high 
levels of Hb-CO, death.1, 6 
CO is produced endogenously from the oxidation of the haem cofactor,7 which releases CO, 
iron and biliverdin (Scheme 1.1). Biliverdin is subsequently reduced to bilirubin by biliverdin 
reductase. This transformation can be seen visually in a bruise, where the initial injury liberates 
the O2-haem complex, giving the skin a red-purple colour.8 As O2 is dissociated, the bruise 
turns blue, and eventually yellow as haem is converted to bilirubin.8 The yellow of bilirubin is 
also observed in jaundice and in urine.8 
The catabolism of haem is catalysed by the protein haem oxygenase,6 which is present in two 
isoforms, a constitutive isoform, haem oxygenase-1 (HO-1) and an induced isoform, haem 
oxygenase-2 (HO-2). These enzymes are ubiquitous in the human body, with high 
concentrations in the brain, spleen, liver, smooth muscle tissues and vascular endothelial cells, 
and are involved in a number of physiological processes mostly related to stress response.6, 9 
The two isoforms of haem oxygenase help control the concentration of haem within the body.7 
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Scheme 1.1: Breakdown of haem by haem oxygenase, where X = O2, NO, CO or H2S, 
depending on the conditions (CO origination circled)3 
 
86% of CO produced in humans is from the oxidation of haem. The remaining 14% of CO 
found in human bodies is generated from lipid peroxidation, photo-oxidation, bacteria and 
xenobiotics.3 
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CO interacts with several proteins, most containing the haem moiety, such as cytochrome c 
oxidase, guanylate cyclase, BK potassium channels and NADPH oxidase.10 
The knowledge that endogenously produced CO contributes to important intracellular 
functions has changed the way the molecule is viewed. It has since been found to display a 
variety of protective effects across a range of pathologies. As a result, the use of CO has 
emerged as a new therapeutic strategy in medicine. 
1.2 CO as a Therapeutic Agent 
Since the discovery that CO not only plays a role in signalling within the cell, but also displays 
protective effects, new areas of investigation have opened up regarding the biological 
properties of the gas.11 
Gaseous CO has been shown to have a wide range of effects, including vasodilatory, 
antiinflammatory, antiproliferative, antiapoptotic, and antihypoxia effects, and also protects 
from tissue reperfusion injury (restoring blood flow to a tissue or organ).8 CO provides 
protection from organ graft rejection in mouse to rat transplantation experiments, in which the 
group exposed to 400 ppm CO for two days after the operation survived up to ten times longer 
than the group that breathed only air.12 It has also been shown to improve cardiac energetics 
and safeguard the heart during reperfusion after cardiopulmonary bypass surgery in pigs.13 In 
three rodent models, CO reversed already established pulmonary hypertension, a type of high 
blood pressure that affects the arteries both in the lungs and in the right side of the heart.14 
Due to the antiinflammatory effects displayed by CO, it was suggested by Lee that CO could 
be used as a treatment for sepsis (systemic inflammation in response to an infection).15 Sepsis 
remains a primary cause of death from infection, resulting from multiple organ dysfunction 
and eventually failure.15 
It is thought that some of the biological effects displayed by CO are mediated through the 
binding of CO to metal centres.10 For example, the copper centres in mitochondrial cytochrome 
c oxidase are targeted by CO, resulting in a decrease in consumption of molecular oxygen and 
an increase in production of reactive oxygen species (ROS).10 
The use of CO gas as a therapeutic agent is limited owing to its toxicity at high concentrations 
and complete lack of specificity.16 To circumvent this problem, Green and co-workers 
suggested using molecules that release CO to deliver the gas molecule in a controlled manner.17 
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These molecules display an expansive range of effects, including antiproliferative and 
antiplasmodial. 
1.3 Malaria 
Malaria is one of the most prevalent parasitic diseases worldwide.18, 19 In 2015 alone, there 
were a reported 212 million new cases of malaria, which amounted to approximately 429 000 
deaths.20 The disease is caused by the Plasmodium parasite, which is spread to humans by the 
female Anopheles mosquito. Five species of Plasmodium cause malaria in humans: P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi.21 P. falciparum causes the most 
severe malaria cases, and most malaria-related deaths are attributed to P. falciparum.18, 21 
P. falciparum has proven to be the deadliest and most difficult species to combat due to the 
rate at which it develops resistance towards antimalarial drugs. Chloroquine (Figure 1.1A), a 
common antimalarial drug, has been rendered drastically less effective due to the rise in 
chloroquine resistant strains of P. falciparum.22 
 
Figure 1.1: Chemical structures of chloroquine (A), ferroquine (B) and artemisinin (C) 
 
The current recommended treatment for malaria is artemisinin-based combination therapy 
(ACT), which consists of an artemisinin derivative, and a partner drug. Combination therapy 
is employed to combat the rise in resistance. With that being said, artemisinin (Figure 1.1C) 
resistance is on the rise, and resistance of P. falciparum is rife across mainland Southeast 
Asia.23 The increased resistance to current treatments calls for research into drugs that are not 
susceptible to current drug resistant strains. 
Ferroquine (Figure 1.1B), a ferrocenyl-derivative of chloroquine, has managed to overcome 
the resistance gained against its parent compound. It exhibits potent in vitro and in vivo efficacy 
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against numerous chloroquine-resistant and chloroquine-sensitive strains of Plasmodium.24, 25 
Ferroquine is currently in phase 2 clinical trials.26 
Due to the success of ferroquine, other biologically important organic and organometallic 
molecules have been modified to include the ferrocenyl moiety in order to improve activity. 
For example, benzimidazole, a bicyclic benzo-fused imidazole compound, whose derivatives 
have displayed potent antitumour, antiparasitic and antimicrobial activity,27 were 
functionalised with one or two ferrocene moieties, which increased the efficacy against 
chloroquine-resistant and chloroquine-sensitive strains of P. falciparum.28 
Furthermore, it has been shown by numerous groups that CO contributes immensely to the 
protective effects of HO-1 against cerebral malaria.29-31 This is thought to be via CO binding 
to prosthetic haem groups of cell-free haemoglobin, forming carboxyhaemoglobin, which is 
not easily oxidised.31 This restrains the molecule, not allowing it to contribute towards the 
pathogenic effects of cell-free haemoglobin,32 and prevents the proinflammatory33 and 
cytotoxic34, 35 effects associated with haem release from haemoglobin. 
Despite this, not much research has been performed into CO-releasing molecules for the 
treatment of malaria infections. 
1.4 CORMs and other metal carbonyls 
CO-releasing molecules (CORMs) are an attempt to exploit the beneficial properties of CO, 
while minimizing the toxic properties of the gas.36 Many CORMs have now been synthesised 
with a range of functions in mind, including specificity and targeting.36 
CORMs exhibit antiapoptotic properties, antiinflammatory effects, antimicrobial activity, 
applications in organ preservation, and therapeutic potential in vascular disease.37 A partial 
explanation for the activity displayed by CORMs could be the accumulation of metal-carbonyl 
complexes inside the target cells, leading to high concentrations of CO within the cell, in 
addition to the metal-co-ligand fragment.38 The vacant coordination site of the metal-co-ligand 
fragment could then become occupied by solvent molecules or could allow the binding of 
biomolecules.9 These adducts may possess biological activity of their own, which could result 
in desirable or undesirable effects.16 
Properties of CORMs, such as CO-release rates and solubility in aqueous media, need to be 
fine-tuned. This is most easily achieved by using metal-carbonyl compounds as CO releasing 
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molecules, which can be modified by altering the co-ligands bulk, basicity/acidity and charge.39 
Most CORMs are organometallic carbonyl complexes with a metal centre in a low oxidation 
state.16 Since the development of the first CORMs, it has been reported that a number of 
different molecules release CO under physiological conditions. These include complexes with 
a wide variety of metal centres, including ruthenium, iron, manganese, vanadium, cobalt, 
iridium, chromium, rhenium, molybdenum and tungsten.16 
Although organometallic carbonyl complexes represent the simplest way to form CORMs, not 
all CORMs are metal-based. 
1.4.1 Non-metal-based CORMs 
Several purely organic CO releasing molecules have been established. Haloalkanes, such as 
CH2Cl2, CHI3 and CHBr3 are metabolised to release CO.8 These haloalkanes have the ability 
to protect the vasculature against oxidative stress and injury, inhibit the proliferation of 
vascular smooth muscle cells, modulate the activity of various immune system cells, and 
enhance the production of antiinflammatory cytokines, among other effects.8 
Sodium boranocarbonate, named CORM-A1, is the only known non-metal-based CORM 
capable of releasing CO under aqueous conditions.40 
1.4.2 Metal-based CORMs and Other Metal Carbonyls 
Organometallic complexes present structural and stereochemical variety, with the possibility 
of rational ligand design and display a variety of mechanisms of action.41 
As previously mentioned, CORMs based on metal-carbonyls can have a variety of metal 
centres, some of which will be discussed below. 
1.4.2.1 Ruthenium carbonyls 
The original patent regarding metal-based CORMs as therapeutic agents filed in 2002 
contained two Ru-based complexes for biological work, CORM-2 and CORM-3  
(Figure 1.2).8, 42 
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Figure 1.2: Structures of CORM-2 and CORM-38 
 
Owing to the commercial availability of CORM-2, as well as it being one of the first reported 
CORMs, it has received a considerable amount of attention.8, 42 Many papers have been 
published documenting the biological use of CORM-2. They cover a wide range of 
applications, including, but not limited to, inducing vasorelaxation,43 inhibiting cytokine-
induced inflammatory response44 and exhibiting antiproliferative effects on human T-cells.45  
CORM-3 was the first water-soluble CORM to be tested in biological systems.8 It displays 
bactericidal properties against a range of microorganisms, including Staphylococcus aureus, 
Pseudomonas aeruginosa and Escherichia coli.9, 36 CORM-3 was able to decrease the bacterial 
count in the spleens of immunosuppressed mice in a similar manner as observed in 
immunocompetent mice, suggesting a direct antibacterial effect, rather than a host-mediated 
effect of the CORM.11 It exhibits bactericidal properties against both normal and antibiotic 
resistant strans of P. aeruginosa, a common human pathogen, both in vivo and in vitro, which 
is mediated by the inhibition of bacterial respiration.11 This microbe displays higher sensitivity 
towards CORM-3 than to host macrophages, and it was suggested that this is due to a greater 
accessibility of CO to the respiratory chain enzymes in the bacterium.11 It was demonstrated 
unambiguously that CORM-3 is a powerful inhibitor of microbial respiration, and that the 
interference of respiratory metabolism correlates temporally with a rapid loss of bacterial 
viability.46 
The mechanism of CO-release is unknown, and the rate of release is slow in pure water, but 
very rapid in the presence of myoglobin.8 This is a common observation for CORMs, which 
often display faster CO-release in the presence of myoglobin.47 When CORM-3 is dissolved in 
phosphate buffer for 24 hours, the complex is deactivated and does not release CO.8 The slow 
dissociation of CO in water coupled with the fast dissociation of CO in the presence of 
myoglobin, along with the simple deactivation of the complex, makes CORM-3 ideal for use 
as a therapeutic CORM.8 Solutions can be prepared and delivered without notable loss of CO, 
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which will be released after administration. The deactivated complex provides a reference 
sample that does not release CO, and thus the effects of the released CO can be investigated.8 
Yabluchanskiy and co-workers showed that CORM-3 can display neuroprotective or 
neurotoxic effects after intracerebral haemorrhage depending on the time of administration.48 
It was suggested by Desmard and co-workers that the bactericidal effects displayed by CORM-
2 and CORM-3 are amplified due to direct transfer of CO from the CORM to its potential 
target.10 
1.4.2.2 Iron carbonyls 
A number of [(η4-2-pyrone)Fe(CO)3] have been reported and tested for CO-release and 
toxicity. Some of these complexes are shown in Figure 1.3, along with two other iron-carbonyl 
complexes. 
 
Figure 1.3: Three [(η4-2-pyrone)Fe(CO)3] CORMs (D – F) and two other Fe-based CORMS 
 
Complexes D – H all release CO. Complex D exhibits vasodilatory effects of aortic rings pre-
contracted with phenylephrine.49 [CpFe(CO)3]+ was found to release CO at a rapid rate.42 
Subsequently, similar complexes with substituted Cp rings and dicarbonyl-halide complexes 
were studied.50, 51 
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1.4.2.3 Manganese carbonyls 
There has been much interest in manganese complexes in recent years because the complexes 
often display antibacterial,52 anticancer53, 54 and antifungal properties.55 [Mn2(CO)10] (Figure 
1.4) was first described as a CORM in the initial publications on the subject, and Mn(I) 
carbonyl complexes are known to release CO.17, 42 It induces vasodilation upon CO-release, 
which occurs upon irradiation with light.17 [Mn2(CO)10] reportedly attenuates the inflammatory 
response in the lungs of thermally injured mice,56 and activates KCa channels in arteriole 
smooth muscle cells.57 
 
Figure 1.4: Photoactivatable CORM, [Mn2(CO)10] 
 
[Mn(CO)5X] (where X = Cl, Br, I) all release CO in the presence of myoglobin at half-lives of 
t1/2 = 970, 245, 384 minutes, respectively.50 [Mn(CO)5Br] greatly reduces the viability of 
Escherichia coli and Staphylococcus aureus, but the bactericidal activity is nulled in the 
presence of myoglobin.58 
Other manganese complexes, such as [Mn(CO)4X2]- (where X = Br, I, MeC(O)S) release CO 
relatively rapidly to myoglobin with half-lives of t1/2 = <2, 12, 32 minutes, respectively.59 
[Mn(CO)4Br2]- displays no cytotoxicity at 100 µM.59 [Mn(CO)4(SC(O)Me2)]- does not 
suppress the formation of [NO2]- in murine RAW264.7 macrophages at 100 µM concentration, 
but does induce vasodilation.59 
Ligand-functionalised polymers were demonstrated as carrier systems for manganese 
tricarbonyl-based CORMs.60 Non-toxic carrier systems must be chosen carefully because the 
metal-polymer adduct may display toxicity even if neither the metal nor the polymer display 
toxicity on their own.60 
It was demonstrated that Mn(III)-salen complexes affect cell viability by inducing apoptosis in 
MCF-7 (human breast cancer) and CCL228 (colon cancer) cells.61 
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Mn(I) tricarbonyl complexes developed by Schatzschneider et al., based on the [2 + 1] 
approach, with a functionalised 2,2’bipyridyl and a known antifungal azole derivative (Figure 
1.5), displayed potent antifungal activity towards L. major and T. brucei, with IC50 values 
ranging from 2 – 5 µM.62 
 
Figure 1.5: General structure of Mn(I) tricarbonyl complex synthesised by Schatzschneider 
et al., where R1 = H or COOCH3 and R2 = known antifungal agent, clotrimazole, 
ketoconazole or miconazole.62 
 
1.4.2.4 Rhenium carbonyls 
Rhenium carbonyl complexes have been shown to display anti-cancer,39, 63-67 anti-malarial28 
and anti-trypanosomal activity.68 There is a review by Gasser et al. titled the Underestimated 
Potential of Organometallic Rhenium Complexes as Anticancer Agents,69 which includes 
many Re(I) carbonyl complexes. Their potential is unmistakeable, and more research into their 
biological activity is necessary. 
A rhenium CORM was synthesised by Zobi and co-workers using the biocompatible scaffold 
cyanocobalamin, and was named B12-ReCORM-2.70 In this heterodinuclear complex, the 
rhenium(II) moiety is coordinated to the axial cyano group of the cyanocobalamin (Figure 
1.6). B12-ReCORM-2 exhibits cytoprotective effects against ischemia-reperfusion injury in the 
rat model, but displays poor cellular uptake.70 
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Figure 1.6: Structure of B12-ReCORM-270 
 
Rhenium(I) tricarbonyl complexes have been shown to exhibit potent antiproliferative activity 
against a range of different cancer cell lines. A series Re(I) tricarbonyl complexes displayed 
IC50 values ranging from 1 – 5 µM against HeLa cells (cervical cancer).63, 64 Furthermore, a 
series of selenium rhenium(I) tricarbonyl complexes displayed excellent activity (5 µM IC50) 
against breast cancer MCF-7 cell line, while Re(I) tricarbonyls based on the [2 + 1] approach 
displayed potent activity (IC50 = 2 – 4 µM) against the breast cancer MDA-MB-468 cell line.65, 
66 
Additionally, it was shown by Illan-Cabeza and co-workers that rhenium tetracarbonyl 
complexes display strong cytotoxicity towards breast cancer MCF-7 tumour cells.71 
Rhenium(I) tricarbonyl indolato complexes J, K and L (Figure 1.7) incite a strong light-
induced antiproliferative effect in HeLa cells.39 
 
Figure 1.7: Rhenium indolato complexes39 
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The cyrhetrenyl benzimidazole displayed in Figure 1.8M was synthesised by Arancibia et al., 
and its antimalarial activity evaluated against chloroquine-sensitive and chloroquine-resistant 




Figure 1.8: Structures of Re(I) tricarbonyl complexes 
 
Gambino et al. reported a series of salicylaldehyde semicarbazone Re(I) complexes, one of 
which is shown in Figure 1.8N, which displayed reasonable antitrypanosomal activity against 
T. cruzi.68 Gambino et al. synthesised a similar series of Re(I) tricarbonyl complexes using 
thiosemicarbazone ligands, which displayed good in vitro activity and decent selectivity 
indexes against T. cruzi (with endothelial cells as a reference). 
1.4.2.5 Chromium carbonyls 
Chromium complexes O (where X = Cl, Br, I) and P release CO in the presence of myoglobin 
with t1/2 ≈ 200 minutes for both complexes.72 Q releases CO upon photolysis.47 Structures are 
shown in Figure 1.9. 
 
Figure 1.9: Selected Cr-based CORMs 
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Nordlander et al. synthesised new organometallic analogues of chloroquine, shown in Figure 
1.10, to overcome the extensive chloroquine resistance developed by Plasmodium.73 These 
complexes displayed potent in vitro activity against chloroquine-resistant and chloroquine-
sensitive strains of Plasmodium. In this case, complex R displayed activity twice as high as for 
the organic ligand against the chloroquine-resistant strain. 
 
Figure 1.10: Half sandwich Cr(I) tricarbonyl complexes synthesised by Nordlander et al.73 
 
1.4.2.6 Molybdenum carbonyls 
[Mo(CO)5X]- (Figure 1.11T), where X = Cl, Br, I, release CO in the presence of myoglobin 
with t1/2 = 718 – 2440 minutes.72 [Mo(CO)5Br]- greatly reduces the viability of Escherichia coli 
and Staphylococcus aureus, but the bactericidal effect is eliminated in the presence of  
myoglobin.1, 58 In the rat model, symptoms of arthritis are diminished when treated with T (X 
= Br).74 
 
Figure 1.11: Selected Mo-based CORMs 
 
Molybdenum tricarbonyls with tridentate N-donor ligands similar to that of complex V exhibit 
antibacterial activity against Helicobacter pylori.75 
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Salicylaldimine Mo(II) dicarbonyl complexes synthesised by Aziz et al. displayed decent 
antibacterial (against S. aureus and E. coli) and antifungal (against A. flavus and A. niger) 
properties.76 
Known antituberculosis drug, isoniazid, was coordinated to an Mo tricarbonyl core by 
Jesudurai and Vancheesan, although the biological effects were never evaluated.77 
1.4.2.7 Tungsten carbonyls 
Along with tungsten complexes similar to complexes O, P, T and U, (Figure 1.9, Figure 1.11) 
are a six-coordinate tungsten-carbonyl complex with a TPPTS ligand (Figure 1.12W) and a 
seven-coordinate tungsten-carbonyl complex with two bidentate acac ligands (Figure 1.2X). 
CO dissociates from W upon irradiation with light.78 Complex X releases CO with t1/2 = 76 
minutes.72 
 
Figure 1.12: Selected W-based CORMs 
 
You et al. coordinated a W(0) aqua, carbonyl complex to the known antibacterial drug, 
norfloxacin. The complex displayed potent in vitro antibacterial activity against E. coli, B. 
dysenteriae and S. auseus. The complex was more efficacious than the organic parent drug.79 
Ditungsten carbonyl Schiff base complexes synthesised by El-Medani et al. displayed decent 
in vitro antibacterial activity against E. coli and S. aureus, but were not as potent as the control 
antibacterial agent, tetracycline.80 
1.5 Mechanisms of CO-release from CORMs 
CO can be released from an organometallic carbonyl complex in a variety of modes, namely 
thermal dissociation, by the presence of strong cis π-donor ligands, via an associative 
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mechanism, by oxidation of the metal centre, by decomposition by an enzyme, by direct 
transfer of CO to a haem protein, and by photochemical release.81 
Most metal-carbonyl compounds will release CO upon thermal activation.81 When heated, the 
M-CO bond is broken and the gas is released.81 When this process is dissociative, the vacant 
coordination site is occupied by a different ligand. This approach is extensively used in the 
synthesis of organometallic complexes when starting from simple metal-carbonyls, such as 
Fe(CO)5 and Mo(CO)6.81 However, the use of thermally activated CORMs in biological 
systems is limited, owing to the high temperatures needed for dissociation to occur.81 For 
thermal dissociation of CO to occur at 37°C, it would require the complex to be fairly unstable 
at room temperature. 
Strong π-donor ligands in a cis position to the CO labilises the CO, allowing dissociation under 
mild conditions.82 A few examples of strong π-donor ligands are O2-, OH-, OR-, NHR- and  
NR2-.82 These ligands are formed by deprotonation in basic media of the coordinated ligands 
OH-, H2O, HOR, NH2R and NR2H, respectively.82 Due to strong π-donor ligands being formed 
by deprotonation, the dissociation of CO is considered pH dependent, and can be used for 
release of CO into specific tissues.81 For example, a CORM could be orally ingested and move 
through the stomach without dissociation, and only release CO when it reaches the intestine, 
where the pH is higher and deprotonation occurs.81 
CO dissociation via an associative mechanism occurs when an incoming ligand forms a new 
metal-ligand bond with the metal centre. When this takes place, the coordination number of the 
complex increases and one of the M-CO bonds elongates and breaks.83 CO gas is then released 
and a new metal-ligand bond is fully formed.83 
In biological systems, the most common oxidant is dissolved molecular oxygen, which can 
interact directly with the metal centre.81 The metal is oxidised by the transferral of electrons 
from the metal centre to the O2, weakening the metal-carbonyl bond, and eventually breaking 
it.81 Thus, if a co-ligand of an organometallic carbonyl complex is displaced under 
physiological conditions, dissolved O2 can occupy the free coordination site and induce metal 
oxidation and subsequently, CO-release.81 This mechanism could be used to target specific 
tissues, owing to the increased lability of some co-ligands after protonation (e.g. histidine and 
pyridine).81 Reactive oxygen species and reactive NO species (NOS) may also act as oxidants 
and lead to CO-release.81 
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CO can be released due to the decomposition of the complex by enzymes or proteins in vivo. 
Certain ligands will be metabolised by enzymes thus triggering the decomposition of the 
organometallic carbonyl complex and subsequent release of CO.81 Esterase-mediated release 
of CO from a cyclohexadienyl-acetate tricarbonyl-iron CORM is shown in Scheme 1.2. 
Ligands that are good substrates for a specific enzyme could be chosen to exert some control 
over the CO-release.81 
 
 
Scheme 1.2: Esterase-mediated CO-release81 
 
Release mechanisms that are of particular interest are those which allow a certain degree of 
control over the time and place of CO-release. Using CORMs that release CO upon irradiation 
with light (photo-CORMs) is an approach that permits this controlled, specific delivery. 
1.6 Photo-CORMs 
Photo-CORMs present a way to achieve precise spatial and temporal control of the biological 
activity of CORMs. These photo-CORMs release CO only upon irradiation with a specific 
wavelength of electromagnetic radiation, and thus can be stored and transported in aqueous 
aerated solution as long as it is not exposed to light.9 Additionally, the amount of CO released 
is directly dependent on the amount of light delivered to the target. Therefore, the dosage of 
CO can be defined.84 The general reaction scheme for photoactivated CO dissociation is shown 
in Scheme 1.3. 
 
Scheme 1.3: General reaction for photoactivated CO-release 
 
The first visible-light-activated CORM to display a potent antimicrobial effect against 
Escherichia coli was synthesised by Ward and co-workers, and is shown in Figure 1.13.85 
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Figure 1.13: Tryptophan-containing Mn(I) tricarbonyl acetonitrile core85 
There are certain desirable properties that a photo-CORM should possess. It should be: 
• Soluble in aqueous solution or DMSO (commonly used for drug delivery)84 
• Stable in aerated aqueous media at physiological temperatures. Although spontaneous 
decay of CORMs at known rates is expected, a photoCORM should only release CO 
when triggered by light.84 
• Photoreactive at wavelengths of light where transmission is optimal. Penetrative depth 
of electromagnetic radiation into tissue is strongly dependent on the wavelength of 
light. Short wavelength radiation is the least penetrative, and the depth peaks in the near 
infrared region of the spectrum (700 – 1100 nm).84 
Nagel and co-workers synthesised a manganese(I)-tricarbonyl CORM with a tridentate tris(2-
picolyl)amine ligand and a bromide counter-ion (Figure 1.14). The CORM displayed no 
antimicrobial activity against Escherichia coli in the absence of light, although it was 
internalised by the microbe. Subsequently, after photoactivation, a reduction in growth rate of 
the bacteria was observed. This suggests that the complex is not toxic to the bacteria, but rather 
that the CO released after photoactivation has antimicrobial activity.9 
 
Figure 1.14: Manganese-based photo-CORM9 
 
A manganese(I)-tricarbonyl complex with tridentate tris(pyrazolyl)methane ligand and a PF6- 
counter-ion displayed photoinduced cytotoxicity towards HT29 colon cancer cells comparable 
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to that of the established anticancer agent 5-fluorouracil, while having no effect when kept in 
the dark.86 
1.7 CO Detection 
Detecting the rate and amount of CO released from a CORM is an important part of the 
characterisation process of the complex. Proper targeting of the CORM requires a suitable half-
life profile for CO-release so that the CORM can reach the intended site.16 
Ideally, quantification of the amount of CO released by a CORM should be done in vitro or in 
vivo.84 
Quantum yield for CO-release (φCO) at the excitation wavelength (λex) is the most quantitative 
parameter with regard to the photoreactivity of a CORM.84 φCO would be reported in units of 
moles of CO released per Einstein of light (one mole of photons) absorbed.84 Although, from 
a therapeutic standpoint, a more important parameter would be the rate of CO production, 
because this establishes the number of moles of CO released per unit time.84 
Apart from practical methods of CO-release measurements, theoretical approaches were found 
to give accurate evaluations for CO-release. This method used density functional theory, a 
computational quantum mechanical model, to determine the rates of CO-release from 
CORMs.87 
There are a variety of methods that can be utilised to determine the amount and rate of CO 
released from a CORM, some of which are discussed below. 
1.7.1 Gas Chromatography 
Gas chromatography can be used to separate CO from other volatile compounds, in order for 
accurate quantitation of CO to be performed. In gas chromatography, the mixture is passed 
through a heated column that is packed with a sorbent or with molecular sieves. An inert gas 
(carrier gas) phase elutes the CO and other volatile compounds in succession, based on their 
molecular size and/or absorption coefficients specific for each packing material.88 A detector 
at the end of the column quantifies the amount of CO released. There are a number of different 
types of detectors available for quantitation of CO using gas chromatography. 
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Gas chromatography coupled to mass spectrometry (GC-MS) can be used for CO-release 
quantitation.84, 88 This type of detector is based on the vapour-phase molecules emerging from 
the column with a stream of high-energy electrons, which convert some of the molecules to 
ions that are then accelerated in an electric field.88 The ions are separated according to their 
mass to charge ratio (m/z). Bartolucci and co-workers used a programmed temperature 
vaporising injector, a porous layer open tubular column with molecular sieves and a 
programmable temperature oven for CO detection.89 By monitoring the m/z = 28 peak, they 
demonstrated low detection limits (10 ng/g) and a dynamic range (50 – 2500 ng/g), due to the 
sensitivity of the detector and the good separation of gases in the column.84 
The flame ionisation detector (FID) is the most common detector used in a gas 
chromatographic system. It is based on the combustion of organic compounds in a flame. For 
analysis of CO, the samples must first be dried, pre-concentrated and then separated from 
hydrocarbons on a pre-column, due to the fact that hydrocarbons will be detected by the FID. 
The sample is directed through the analytical column and the emerging CO is reduced to CH4 
in a heated catalytic reduction tube (methaniser), which can then be quantitated using the FID 
detector.88 
1.7.2 Manometric Techniques 
The evolution of CO gas from a compound can be measured in a manometric fashion. The gas 
is evolved in a closed container and the volume is measured using a manometer.58 
1.7.3 Myoglobin 
By far the most common technique used to determine the amount of CO released from a CORM 
is the myoglobin assay.17, 88 With this method, CO reacts with myoglobin to form 
carboxymyoglobin. The electronic spectrum changes significantly and can be visualised using 
ultraviolet-visible spectrophotometry (UV-Vis).90 Due to the reactivity of myoglobin with 
molecular oxygen (O2), the measurements must be performed in the presence of dithionite, a 
reducing agent.8 Myoglobin reacts rapidly with CO, and removes free CO quickly from the 
solution. If the loss of CO from the CORM is reversible, this could affect the rate of CO-
release.8 The assay is conducted under physiological conditions (pH 7.4 and 37°C). The 
absorbance at 540 nm is measured and the proportion of myoglobin that has converted to 
carboxymyoglobin can be determined.90 
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1.7.4 CO Electrode 
A CO electrode has been produced by World Precision Instruments and has been used to 
determine the concentration of CO in solution.40, 91 The electrode is calibrated using 
Na2[H3BCO2] (CORM-A1).92 The electrode consumes CO throughout the measurement and 
the resulting data corresponds to the liberation of CO from the CORM.8 
1.8 Dendrimers 
Dendrimers are repetitively highly branched macromolecules. Dendrimers have a well-defined 
shape, a central core, and branches emanating from the core.93 An extensive range of 
functionalities can be contained within the dendritic framework.  
 
Figure 1.15: General schematic of a dendritic scaffold94 
 
A dendritic scaffold has four key regions: the core, the repeating branching units, terminal 
groups, and void spaces (Figure 1.15).94 The void spaces can encapsulate molecular cargo, and 
the surface terminal groups bear reactive groups that are easily functionalised to suit the 
intended use of the dendrimer.94 G1 and G2 refer to the generation of the dendrimer (Gn), 
which can range from G1 to G12.94 The dendrimer diameter increases linearly with the 
generation, whereas the number of surface terminal groups increase exponentially with the 
generation.94 
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The active moiety is usually covalently attached to the terminal groups of the dendrimer, which 
brings about a multinuclear compound, often resulting in improved biological activity when 
compared to the mononuclear compound.95 This increase in activity could be due to favourable 
modulation of the stability, solubility and/or lipophilicity of the drug.95 
Dendrimers are able to passively target malignant tissue as a result of the pathophysiological 
properties of solid tumours, such as leaky vasculature and impaired drainage. This leads to a 
property of dendrimers, and, in fact, most nanoparticles, called the enhanced permeability and 
retention effect.60, 96 Consequently, nanoparticles, such as dendrimers, can improve site-
specific drug delivery and subsequently reduce systemic exposure to the drug, reducing side 
effects.96 
Due to the ease of control of the size, surface chemistry and shape of dendrimers, they offer 
various drug-design opportunities and a suitable approach for the delivery of metal-based 
drugs.94 
1.8.1 Metallodendrimers as Biological Agents 
Functionalising dendrimers with metals to form so-called metallodendrimers can increase the 
potency of the dendrimer as a biological agent. Furthermore, this multinuclear method often 
bears the potential drug with an increase in activity and efficacy over their mononuclear 
analogues.97 
Many studies have been performed by Smith and co-workers that give insight into the 
therapeutic potential of metallodendrimers. These studies include functionalising dendrimers 
with a number of different metal moieties, including ruthenium-arene complexes,98 osmium-
arene complexes,99 manganese- and rhenium-Cp and Cp* complexes,100, 101 and rhodium- and 
iridium-Cp* complexes.102 
Following the success of the Pt-based anticancer drug Cisplatin, researchers turned their 
attention to synthesising and evaluating the biological potential of multinuclear Pt-based drugs, 
such as the trinuclear complex synthesised by Boegler et al.103 (Figure 1.16A) and the 
tetranuclear complex synthesised by Brouwer et al.104 (Figure 1.16B). Both potential drugs 
displayed potent activity against a variety of cell lines. 
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Figure 1.16: Structures of two multinuclear Pt-based anticancer drugs 
 
1.8.2 Metallodendrimers as Photo-CORMs 
Macromolecular systems have been used as CORM carriers in attempts to improve 
pharmacokinetic properties.16 Tetranuclear and octanuclear (G1 and G2, respectively) 
[Mn(CO)3]-functionalised metallodendrimers were synthesised by Smith et al. (Figure 
1.17).105 
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Figure 1.17: Poly(propyleneimine) dendrimer functionalised with photoreactive [Mn(CO)3] 
moieties105 
 
These metallodendrimers are the only example of photo-CORMs on a dendritic scaffold. The 
CO-release properties of the dendrimers were investigated, and showed that with an increase 
in dendrimer generation, there was an increase the equivalents of CO released, as expected. 
The study also showed that percentage of CO released increased from the monomer to the 
dendrimer, which could indicate that there is some cooperative CO release, and that higher 
generation dendrimers will release a higher percentage of CO. 
1.9 Nuclear Medicine 
It is apparent that non-invasive detection and therapy of solid tumours at an early stage is 
extremely beneficial.106 Technologies that enable this will move diagnosis and treatment to an 
earlier point in the tumour progression, preventing the spread of cancer to other parts of the 
body, and minimising patient inconvenience and incapacitation.106 Radiopharmaceuticals, a 
radioactive compound combined with a new molecule or a molecule of identified biological 
conduct, can be used to visualise solid tumours.107 
Radioactivity occurs when the nucleus of an atom is unstable, and during the decomposition 
of the nucleus, electromagnetic radiation or particles are emitted in the form of alpha, beta, or 
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gamma rays.108-110 Nucleons (protons and neutrons) in the nucleus of an atom experience a 
binding force stronger than that of the repulsive force due to charge. The competition between 
this nuclear binding force and the electrostatic repulsion determines the stability of the 
nucleus.111 
In the 1930s phosphorus-32, a beta-emitting cyclotron-produced radionuclide, was used for the 
treatment of patients with haematological diseases for the first time. Since then, the use of 
radioisotopes in medicine has expanded dramatically, and they are used for both diagnostic 
imaging (tissue penetration of gamma rays from nuclear decay of positron annihilation) and 
targeted therapy (toxicity of non-penetrating alpha and beta particles).109  
1.9.1 Therapeutic Radiopharmaceuticals 
Therapeutic radiopharmaceuticals are designed to deliver a therapeutic dose of ionising 
radiation to a specific site. Preferably, the molecule should localise at the desired site in an 
adequate concentration to deliver a cytotoxic dose of radiation. The radiopharmaceutical 
should also clear itself from the blood stream and other organs in a period that ensures no 
radiation damage can occur.108 Numerous radionuclides are currently used for the treatment of 
malignancies, almost all of which are alpha- and beta-emitters. Some of the beta-emitting 
radionuclides used for medical applications in oncology are 32P, 89Sr, 90Y, 166Ho, 186Re and 
188Re.108 
1.9.2 Diagnostic Radiopharmaceuticals 
Diagnostic radiopharmaceuticals are used for imaging and consist of molecules labelled with 
gamma- or positron-emitting radionuclides. Single photon emission computed tomography 
(SPECT) and positron emitted tomography (PET) are the two imaging techniques used to 
visualise the radionuclide and provide metabolic and functional information. 
Technetium-99m, a metastable isotope of technetium-99, emits γ-radiation with a half-life of 
6.02 hours.109 It is, and has been for some decades, the radioisotope used in the largest number 
of radionuclide scans, due to its suitable half-life and gamma-energy (140 keV), which are 
beneficial for effective imaging and patient safety viewpoints.108, 109 The distribution problems 
posed by the short half-life of 99mTc are overcome by transporting it in the form of 99Mo (t1/2 = 
60 hours).109 99mTc is then generated from 99Mo using a 99mTc generator.109 
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Rhenium-186 and rhenium-188 are of great interest to researchers as therapeutic analogues of 
99mTc radiopharmaceuticals.109 Although rhenium and technetium behave differently in certain 
conditions, for example, the bisphosphonate complexes,112 the tricarbonyl complexes are 
similar in structure and reactivity.109 
Along with the enhanced permeability and retention effect of dendrimers, 99mTc-based moieties 
on dendritic scaffolds could be used to image solid tumours and, if the complexes are found to 
aggregate in microbes, microbial infections.113  
 
Figure 1.18: Structure of 68Ga-radiolabelled metallodendrimer114 
 
111In is a radionuclide that is clinically available for imaging using gamma-scintigraphy. It has 
a half-life of 2.8 days and decays by electron capture (whereby an electron from a low electron 
shell is absorbed by the nucleus to pair with a proton, which becomes a neutron, resulting in 
the release of an electron neutrino), releasing two gamma-photon emissions at 173 and 247 
keV.108 111In was first introduced as a tumour imaging agent, due to its dispersal in the 
intracellular and extracellular spaces of tumours.115 111In-labelled complexes are often used as 
imaging substitutes for dosimetry determination and biodistribution of 90Y congeners, due to 
their similar coordination chemistry. 
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125I is a radioisotope of iodine with a half-life of 60 days and a gamma-ray photon energy of 
28 keV. It is used primarily in radioimmunoassays and other in vitro tests. Other iodine isotopes 
are used for thyroid SPECT (123I), hormonal disorders or cancerous thyroid pathology observed 
by PET (124I) or SPECT (131I) imaging.108 
68Ga is used as a non-physiological metallic positron emitter for clinical PET imaging. Its use 
stems from the availability of 68Ga from an on-site generator, eliminating the need for a 
cyclotron. It has a half-life of 68 minutes, and decays by 89 % through a positron emission of 
1.92 MeV.108 Figure 1.18 shows the structure of a radiolabelled metallodendrimer synthesised 
by Fukase and co-workers.114 
1.10 Non-invasive Nuclear Imaging Modalities 
SPECT and PET are the two techniques used to visualise the radionuclide in vivo. The different 
techniques come with pros and cons, but, in general, PET is preferred over SPECT due to the 
higher resolution that it is possible to achieve using PET.116 
In SPECT imaging, the radiation is measured by gamma-ray cameras, with gamma-emitting 
radionuclides with energies of approximately 75 – 360 keV.117 SPECT is usually used in 
combination with other imaging techniques, such as magnetic resonance contrast. SPECT/CT 
scans are the most common, where a computed tomography scan (CT) is first performed, 
followed by the SPECT scan, and the images are merged. 
PET imaging also uses the detection of gamma-rays to image the radionuclides. In PET 
imaging, the gamma-rays are formed from the annihilation of positrons. The unstable atom 
lowers its energy by emitting ionising radiation. The emitted particle loses its energy by 
collisions with the atoms in the adjacent tissue.116 When the particle has reached a sufficiently 
low energy, it collides with a free electron, producing two photons of equal energy (511 keV) 
travelling in almost opposite directions, which are detected by the PET camera.116 
The most important advantage that PET imaging has over SPECT imaging is the higher 
sensitivity. PET imaging is more sensitive by two or three orders of magnitude, meaning that 
the detector can detect a higher percentage of emitted events.117 
Due to the longer half-life of single photon emitters, SPECT has a widened observational 
window when compared to PET. This allows biological processes to be observed in vivo over 
a period of hours or days.118 
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1.11 Aims and Objectives 
1.11.1 General Aims 
The general aims of this project were to: 
• Design, synthesise and characterise two series of mono-, tris- and dendritic 
picolylamine ligands 
• Synthesise the metal precursors and coordinate them to the ligands to form the 
respective metallodendrimers 
• Evaluate the CO-release properties of the complexes 
• Radiolabel the ligands with 99mTc 
1.11.2 Specific Objectives 
• To synthesise a series of monomeric and dendritic ligands functionalised with 2-
picolylamine and 4-picolylamine 
 
Figure 1.19: General structure of the 2-picolylamine and 4-picolylamine ligands 
 
• To coordinate the synthesised 4-picolylamine ligands to carbonyl-bipyridyl Mn and Re 
to form the tricarbonyl products 
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Figure 1.20: General structure of the manganese, technetium-99m and rhenium 
metallodendrimers 
 
• To radiolabel the ligands with 99mTc using the isoLink® method 
• To determine the CO-release properties of the Mn(I) tricarbonyl complexes 
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Chapter 2      Synthesis and Characterisation of 
Ligands and Complexes 
2.1 Introduction 
Considering the success of metal-based drugs in the treatment of various illnesses, a range of 
ligands and their group 7 complexes have been synthesised and researched as biologically 
active molecules. Group 7 carbonyl complexes have shown promise as potential  
anticancer,1-6 antibacterial,7 antifungal8 and antiplasmodial agents.9, 10 
2.2 Synthesis and Characterisation of 4-Picolylamine Ligands 
The 4-picolylimine ligand precursors, 4, 5 and 6, were synthesised using known methods.11-13 
The ligand precursors were prepared by reacting 4-pyridinecarboxaldehyde with the suitable 
dendritic scaffold via a Schiff base condensation reaction (general mechanism shown in 
Scheme 2.2), followed by reduction of the imine using NaBH4 to afford the desired ligand 
(Scheme 2.1). 
 
Scheme 2.1: Synthesis of 4-picolylamine ligands 
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The Schiff base reaction was performed in DCM in the presence of MgSO4, used as a drying 
agent to remove the water, which is formed as a by-product (see Scheme 2.2), and prevents the 
reverse reaction from occurring, as all steps in the Schiff-base formation are reversible. The 
reduction was performed in methanol by NaBH4. The 4-picolylamine ligands were isolated as 
brown oils in good to moderate overall yields (Table 2.1). 
 
 
Scheme 2.2: Mechanistic outline of a general Schiff base condensation reaction in water 
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Table 2.1: Physical appearance and overall yield for 4-picolylamine ligands 
Compound Physical Appearance Overall yield (%) 
10 Yellow oil 48 
11 Dark brown oil 76 
12 Light brown oil 41 
 
The 4-picolylamine ligands 10 – 12 are non-hygroscopic, stable in air at room temperature, and 
soluble in acetone, acetonitrile, dichloromethane, methanol, ethanol and dimethylsulfoxide. 
2.2.1 1H and 13C{1H} NMR Spectroscopy 
Analysis of the 1H and 13C{1H} spectra of compounds 4 – 6 and 10 – 12 confirmed that the 
proposed compounds were attained. Figure 2.1 shows the 1H NMR spectrum of ligand 
precursor 6. 
 
Figure 2.1: 1H NMR spectrum of ligand precursor 6 
 
In the 1H NMR spectrum of compound 6, protons Ha and Hb appear as a pair of doublet of 
doublets at 8.65 and 7.65 ppm, respectively. The imine proton, Hd, appears in the expected 
region as a singlet at 8.37 ppm. A cross peak is observed in the COSY spectrum, indicating 
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as a singlet. COSY and HSQC NMR experiments were performed to assign proton and carbon 
signals. 
Figure 2.2 shows the stacked 1H NMR spectra for ligands 10, 11 and 12, all recorded in 
acetone-d6. 
 
Figure 2.2: Stacked 1H NMR spectra of ligands 10, 11 and 12 
 
From Figure 2.2 it is clear that there is no imine peak, which is observed as a singlet at 
approximately 8.35 ppm in the 1H NMR spectra of ligand precursors 4, 5 and 6 (see Figure 
2.1). This, along with the new methylene singlet (Hc) at ca. 3.80 ppm in each of the spectra, is 
evidence that the reduction was successfully performed. 
In each 1H NMR spectrum, two doublets are observed in the aromatic region, due to the four 
protons on the pyridyl ring. Only two peaks are observed due to the local symmetry in the 
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13C{1H} NMR experiments were performed, accompanied by COSY and HSQC 2-D NMR 
experiments, to aid in the assignment of proton and carbon signals. The 13C{1H} spectra display 
all of the expected peaks in the expected ranges. 
2.2.2 Infrared Spectroscopy 
The infrared spectra of 4-picolylamine ligands 10 – 12 were recorded as pure oils using the 
attenuated total reflectance sampling technique, which allows the user to examine the sample 
directly without further preparation. Two characteristic absorption bands for the aromatic C=N 
stretching vibration and the NH stretching band are displayed. Table 2.2 shows important 
absorption bands in the infrared spectrum of the 4-picolylamine ligands. 
Table 2.2: Important infrared absorption bands for 4-picolylamine ligands 
Compound C=Naromatic (cm-1) NH (cm-1) 
10 1600 3274 
11 1600 3270 
12 1602 3270 
 
The infrared absorption bands arise in the expected regions for both the C=N ring stretch and 
the NH stretching bands. 
2.2.3 Mass Spectrometry 
Mass spectrometry was utilised to further confirm the presence of the proposed structures. 
Table 2.3: EI mass spectrometry results for 4-picolylamine ligands 
Compound m/z Fragment 
10 149.07 [M-H]+ 
11 419.26 [M]+ 
12 678.45 [M-H]+ 
 
Table 2.3 displays the mass spectrometry results for 4-picolylamine ligands. These results, 
accompanied by the other characterisation techniques used, suggest that the proposed structures 
were obtained. 
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2.3 Synthesis and Characterisation of 2-Picolylamine Ligands 
The 2-picolylamine ligands (13, 14 and 15) were synthesised in a similar manner to that of the 
4-picolylamine ligands, following literature procedures (see Scheme 2.3): Schiff base reaction 
in DCM to afford the ligand precursors,11, 12, 14 7, 8 and 9, followed by reduction with NaBH4 
to yield the desired ligands. The 1H NMR spectra of the 2-picolylamine ligands are shown in 
Figure 2.4. 
 
Scheme 2.3: Synthesis of 2-picolylamine ligands 
 
Similarly to the synthesis and purification of the 4-picolylamine ligands, the imine formation 
was performed in DCM, and purification was accomplished by washing the DCM layer with 
copious amounts of water. The reduction was performed in methanol using sodium 
borohydride as the reducing agent, under Ar, after which the excess NaBH4 was quenched with 
water, and a liquid-liquid extraction (DCM/water) was employed to remove the remaining 
starting material. The 2-picolylamine ligands were isolated as brown oils in moderate to low 
overall yields (Table 2.3). 
 
Table 2.3: Physical appearance and overall yield for 2-picolylamine ligands 
Compound Physical Appearance Overall yield (%) 
13 Yellow oil 31 
14 Dark brown oil 62 
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15 Dark brown oil 61 
 
Ligands 13 – 15 are air-stable at room temperature, are soluble in methanol, ethanol, acetone, 
DCM, chloroform and DMSO, and sparingly soluble in water. 
2.3.1 1H and 13C{1H} NMR Spectroscopy 
1H and 13C{1H} NMR experiments were performed to ascertain whether the desired products 
were present. Figure 2.3 shows an assigned 1H NMR spectrum for ligand precursor 7, as a 
representative for the ligand precursors 7 – 9. 
 
Figure 2.3: 1H NMR spectrum of ligand precursor 7 
 
1H and 13C{1H} NMR spectroscopy were used to confirm that the proposed structures were 
obtained. Figure 2.3 shows the 1H NMR spectrum of ligand precursor 7. The characteristic 
imine peak, Hf, integrates for one proton, and is observed as a doublet at 8.35 ppm, due to 
coupling to proton Hg, as confirmed by a COSY NMR experiment. Unlike the 4-pyridyl ligands 
and ligand precursors, there is no local symmetry in the pyridyl ring, resulting in four separate 
aromatic peaks (Ha, Hb, Hc and Hd), each integrating for one proton. The aliphatic proton peaks 
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Figure 2.4: stacked 1H NMR spectra of ligands 13, 14 and 15 
 
The lack of a sharp imine proton signal at ca. 8.35 ppm in all the spectra in Figure 2.4, in 
conjunction with the formation of a new methylene peak observed at approximately 3.80 ppm, 
signifies the reduction of the imine to form the desired amine. 
The aromatic peaks are due to the four non-equivalent protons on the pyridyl ring. The four 
peaks each integrate for one proton, which is consistent with the proposed structures. The 
aliphatic peaks are typical of the respective cores. 
In the 13C{1H} NMR spectra of the ligands, the aromatic peaks arise between 121 and 161 
ppm, as expected, while the aliphatic peaks are observed in the range of 11 – 55 ppm. COSY 
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2.3.2 Infrared Spectroscopy 
Infrared spectroscopy was used as further evidence to demonstrate the formation of the desired 
ligands. The 2-picolylamine ligands display two characteristic absorption bands: the C=N 
stretching band, and the NH stretching band. The important absorption bands are summarised 
in Table 2.4, all of which lie in the expected regions. 
Table 2.4: Important infrared absorption bands for 2-picolylamine ligands 
Compound C=Naromatic (cm-1) NH (cm-1) 
13 1592 3290 
14 1591 3291 
15 1591 3288 
2.3.3 Mass Spectrometry 
EI mass spectrometry was utilised to further confirm the structural integrity of the proposed 
ligands. The data are summarised in Table 2.5. 
Table 2.5: EI mass spectrometry results for 4-picolylamine ligands 
Compound m/z Fragment 
13 149.08 [M-H]+ 
14 419.90 [M]+ 
15 679.44 [M-H]+ 
2.4 Re(I)(bpy) [2 + 1] Complexes 
The Re(I)(bpy) [2 + 1] complexes 16 - 18 were formed by abstracting the chloride ion from 
[Re(bpy)Cl(CO)3] (synthesised by reaction of [ReCl(CO)5] with 2,2’-bipyridyl) using silver 
triflate before the addition of the appropriate ligand in the appropriate stoichiometric ratio 
(Scheme 2.4). Anion exchange was then performed using ammonium hexafluorophosphate. 
The [2 + 1] strategy is a useful tool to impart desired properties on a complex. The monodentate 
and bidentate moiety can be modified to give the molecule appealing characteristics, such as 
solubility in aqueous media. 
Chapter 2     Synthesis and Characterisation of Ligands and Complexes  P a g e  | 45 
 
 
Scheme 2.4: Synthesis of Re(I)(bpy) monodentate complexes 16, 17 and 18. 
 
The [2 + 1] Re(I) complexes were isolated in very low yields as brown powders (Table 2.6). 
Table 2.6: Physical appearance and yield for Re(I) [2 + 1] complexes 
Compound Physical Appearance Yield (%) 
16 Brown powder 19 
17 Brown powder 12 
18 Brown powder 11 
 
The Re(I) complexes 16, 17 and 18 are air-stable, and soluble in DCM, methanol, ethanol, 
acetone and DMSO. 
2.4.1 1H and 13C{1H} NMR Spectroscopy 
Complex 16 was synthesised by abstracting the chloride from [Re(bpy)Cl(CO)3] before 
addition of ligand 10. An anion exchange was then performed using ammonium 
hexafluorophosphate. The 1H NMR spectrum for complex 16 is shown in Figure 2.5. 
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Figure 2.5: 1H NMR spectrum of complex 16 
 
Integration of the aromatic proton signals shows that the bipyridyl moiety and ligand 10 have 
been added in a one-to-one ratio, suggesting the presence of the desired complex. The 
characteristic peak assigned to Hd appears at 3.78 ppm compared to 3.80 ppm in the ligand, 
which suggests complexation via the pyridyl nitrogen, as opposed to the secondary amine 
nitrogen. The proton peaks attributed to the bipyridyl moiety, as well as the pyridine moiety 
appear in the region from 7.45 – 9.48 ppm. Overlap of signals Ha and Hk result in a multiplet 
at 8.45 ppm. 
The 13C{1H} NMR spectrum shows all the expected peaks, which have been assigned using 
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Figure 2.6: 1H NMR spectrum of complex 16b 
 
The complexation reaction to form complex 16b was performed in methanol instead of DCM. 
As can be seen from Figure 2.6, the characteristic proton signal Hd appears as a singlet at 4.62 
ppm, compared to 3.78 ppm in complex 16. This difference between the two complexes (16 
and 16b) is attributed to solvent effects or protonation of the secondary amine. The protonation 
hypothesis is substantiated by the presence of two PF6 anions in the molecular structure (see 
Section 2.3.4). The aromatic proton peaks are all present, with the correct integration and 
multiplicity. 
Complexation of ligand 11 with [Re(bpy)(CO)3Cl] was performed in DCM to afford the tri-
functionalised complex 17. The 1H NMR spectrum for complex 17 is shown in Figure 2.7. 
a/j 
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Figure 2.7: Assigned NMR spectrum of trifunctionalised complex 17 
 
Figure 2.7 shows that integration of the aromatic proton signals matches that of the proposed 
structure. Upon coordination, there is no significant shift of aromatic proton peak Ha, as 
expected, whereas there is a slight downfield shift of proton peak Hb from 7.30 ppm to 7.43 
ppm upon coordination. Proton Hd remains unshifted upon coordination, suggesting that 
complexation has occurred via the pyridyl nitrogen and not the secondary amine nitrogen. 
The peaks are not well-defined, which may indicate a mixture of mono-, di-, and tri-
functionalised complexes present. Excess metal precursor was used for the reaction, and the 
reaction time was increased to 72 hours without effect. 
The 13C{1H} spectrum (Figure 2.8) displays all of the expected peaks in the expected regions. 
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Figure 2.9: Assigned NMR spectrum of tetrafunctionalised complex 18 
 
Figure 2.9 shows that the aromatic proton peaks of complex 18 are similar to that of complexes 
16 and 17, displaying five peaks with Ha and Hm as an overlapping multiplet. The picolyl 
methylene protons are visible as a singlet at 3.83 ppm (shifted from 3.78 ppm in the ligand). 
The DAB core signals are not as well defined as the aromatic proton signals, exhibiting overlap 
of proton signals for Hf and Hh, as well as Hg and Hj. 
The complexation of the DAB ligand 12 with [Re(bpy)(CO)3Cl] was attempted multiple times 
with different solvents and work up procedures. Using methanol for the complexation reaction 
was found to decompose the product, while DCM and toluene gave similar results. 




o l n b d f/h i g/j 
DCM 
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Figure 2.10: Comparison of 1H NMR spectra of the three Re(I) complexes 16, 17 and 18. 
 
Using Figure 2.10, it can be seen that the aromatic proton peaks, in addition to the picolyl 
methylene peaks, are in similar positions for the three Re(I) complexes. The major differences 
between the complexes lie in the core aliphatic protons. This suggests that the bonding mode 
is the same for all three complexes. 
31P{1H} experiments were performed on complexes 16 – 18 to confirm the presence of the PF6 
counterion. The resulting signal was a heptet at ca. -144.30 ppm, with a coupling constant of 
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2.4.2 Infrared Spectroscopy 
In conjunction with the 1H and 13C{1H} NMR spectroscopy, infrared spectroscopy was utilised 
to indicate the formation of the desired products. Absorption bands attributed to the carbonyl 
moiety, as well as shifts in the pyridyl C=N absorption band are characteristic of complexation. 
Table 2.7 shows the significant absorption bands for the Re(I)(bpy) complexes. 
Table 2.7: Important infrared absorption bands for the Re(I)(bpy) complexes  
Compound C=Naromatic (cm-1) CO (cm-1) 
16 1619 2025 / 1899 
17 1619 2031 / 1907 
18 1619 2028 / 1901 
 
The carbonyl stretching bands appear in the region of approximately 2030 – 1900 cm-1, which 
indicate a facial coordination of the carbonyl groups. 
The shift of the C=N stretching band to higher wavenumbers from approximately 1600 cm-1 in 
the ligand to 1619 cm-1 upon complexation is likely due to the accumulation of positive charge 
on the pyridyl nitrogen, which decreases aromaticity and increases the bond order of the C=N 
bond.15 This shift of the C=N band in pyridine moieties to higher wavenumbers upon 
complexation has been observed in other pyridine complexes.16 This confirms that coordination 
occurred via the pyridyl nitrogen. 
2.4.3 Elemental Analysis and Mass Spectrometry 
High resolution ESI mass spectrometry experiments were used to confirm the proposed 
structure of the Re(I) [2 + 1] complexes 16, 17 and 18, the data of which is displayed in Table 
2.8. ESI+ is a ‘soft ionisation’ technique, meaning that there is little fragmentation. Owing to 
this, the observed fragments have lost only carbonyl groups, which are the most labile. 
Elemental analysis was used to further confirm the structural integrity and purity of the 
complexes. All results were in reasonable limits, confirming high purity of the samples. For 
complex 18, several solvent molecules were present in the sample, as confirmed by 1H NMR. 
This is acceptable as dendrimers are known to incorporate solvent molecules and are 
notoriously difficult to dry.17 
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Table 2.8: HR-ESI+ mass spectrometry results for Re(I) complexes 
Complex m/z Fragment 
16 577.12 [M-PF6]+ 
17 566.07 [M-3PF6]3+ 
18 590.08 [M-CO-4PF6]4+ 
2.4.4 Single-crystal X-ray Crystallography 
The molecular structure of the mononuclear complex 16b was determined by single crystal X-
ray diffraction. The crystal was grown by the slow evaporation of methanol. The molecular 
structure is displayed in Figure 2.11. 
 
Figure 2.11: Representation of the molecular structure of complex 16b. Ellipsoids are drawn 
at the 50 % probability level. 
 
Complex 16b crystallised in the triclinic, centrosymmetric space group P 1  ,with two formula 
units per cell (Z = 2). The molecular structure of complex 16b is represented in Figure 2.11, 
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together with the numbering scheme. Table 2.9 and Table 2.10 show the general X-ray 
diffraction data and geometrical parameters of complex 16b. 
Table 2.9: X-ray diffraction data of complex 16b 
Empirical formula C22H22N4O3Re, 2(PF6), 3(O) 
Formula weight 914.59 
Crystal system Triclinic 
Space Group P 1   
a (Å) 8.3609(5) 
b (Å) 10.5475(6) 
c (Å) 18.7131(11) 
α (°) 95.917(1) 
β (°) 94.552(1) 
γ (°) 93.283(1) 
V (Å3) 1632.71(17) 
Dcalc(mg.cm-3) 1.860 
μ (mm-1) 3.929 
F(000) 886 
T (K) 173 
Crystal colour Yellow 
θ range (°) 2.6 – 28.4 
Index ranges h = -11 to 11 
 k = -13 to 14 
 l = -25 to 25 
Reflections collected 51611 
Independent reflections 8155 
Rint 0.061 
R indices Rl = 0.0346, wR2 = 0.0939 
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The coordination of the 2,2’-bipyridyl forms a five-membered ring with the Re(I) atom. The 
three carbonyl groups are coordinated facially to the metal centre. The geometry around the 
Re(I) atom is distorted octahedral. The trans angles given to the Re-CO (C(11)-Re(1)-N(3), 
C(12)-Re(1)-N(1), C(13)-Re(1)-N(2)) range between 171.89(15) and 176.61(16) °, which is a 
slight deviation from the perfect octahedral angles of 180.00°. The bite angle of the 2,2’-
bipyridyl ancillary ligand (N(1)-Re(1)-N(2)) is 74.79(12) °, which is between the ideal bite 
angle of 90.00 ° for the octahedral geometry and 72.00 ° for the five-membered ring. 
No substantial trans influence is observed as all the ligands trans to the carbonyls are nitrogens 
in pyridyl rings. The Re-CCO bond distances range between 1.924(5) and 1.937(4) Å. 
The molecular structure obtained exhibits two hexafluorophosphate anions for every Re(I) 
centre. This could be due to protonation of the nitrogen (N(4)), although this cannot be proven 
using SCXRD, due to disorder in the packing of the molecule in the crystal structure, and the 
low scattering of X-rays by hydrogen atoms. Protonation of the nitrogen (N(4)) could explain 
the downfield shift observed in the 1H NMR spectrum of complex 16b compared to that of 16 
(discussed in Section 2.3.1). 
Calculated hydrogen bonds show a hydrogen bond between nitrogen N(4) and the oxygen of a 
water molecule located in the crystal lattice. 
 
 
Table 2.10: Selected bond lengths and bond angles for complex 16b 
Selected bond angles Bond angle (°)  Selected bond lengths Bond length (Å) 
C(11)-Re(1)-N(3) 176.61(16)  Re(1)-C(11) 1.927(5) 
C(12)-Re(1)-N(1) 174.02(16)  Re(1)-C(12) 1.937(4) 
C(13)-Re(1)-N(2) 171.89(15)  Re(1)-C(13) 1.924(5) 
N(1)-Re(1)-N(3) 83.80(13)  Re(1)-N(1) 2.173(3) 
N(2)-Re(1)-N(3) 83.48(12)  Re(1)-N(2) 2.179(3) 
 Bite angle (°)  Re(1)-N(3) 2.213(3) 
N(1)-Re(1)-N(2) 74.79(12)    
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2.5 Mn(I)(bpy) [2 + 1] Complexes 
The manganese [2 + 1] complexes, 19, 20 and 21, were synthesised in a similar manner to the 
Re(I) monodentate complexes. The precursor [Mn(bpy)Br(CO)3] was synthesised by reaction 
of [MnBr(CO)5] with 2,2’-bipyridyl. The bromide anion was abstracted with silver triflate from 
[Mn(bpy)Br(CO)3], before addition of the appropriate ligand in the appropriate stoichiometric 
ratio. An anion exchange was then performed using ammonium hexafluorophosphate to afford 
the PF6 salt. The synthesis is shown in Scheme 2.5. 
 
Scheme 2.5: Synthesis of Mn(I)(bpy) monodentate complexes 19, 20 and 21. 
 
The Mn(I) [2 + 1] complexes 19 – 21 were isolated in moderate to low yields, all as yellow 
powders or residues (Table 2.11). 
Table 2.11: Physical appearance and yield for the [2 + 1] Mn(I)(bpy) tricarbonyl complexes 
Compound Physical Appearance Yield (%) 
19 Yellow/orange residue 66 
20 Pale yellow powder 31 
21 Pale yellow powder 40 
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The Mn(I) [2 + 1] complexes 19 – 21 are air-stable, light sensitive, and soluble in methanol, 
ethanol, acetone, DCM, chloroform and DMSO. 
2.5.1 1H and 13C{1H} NMR Spectroscopy 
1H and 13C NMR spectroscopy techniques were used to verify the formation of the desired 
products. The 1H NMR spectrum for monomeric complex 19 is shown in Figure 2.12. 
 
 
Figure 2.12: Assigned 1H NMR spectrum of complex 19 
 
The presence of the bipyridyl peaks in the aromatic region, in addition to the peaks expected 
for ligand 10 gives evidence that complexation has occurred. Proton Ha displays an upfield 
shift from 8.49 ppm in ligand 10 to 8.33 pm in the complex. This is likely due to the 
electropositive metal ion acting as an electron-withdrawing group, deshielding the nearby 
protons. This shift in the proton peak upfield, along with the lack of shift of the picolylamine 
methylene peak Hd serves as proof that complexation has occurred via the picolylamine 
nitrogen and not the secondary amine nitrogen. 
a/k 
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Figure 2.13: Assigned 13C{1H} NMR spectrum of complex 19 
 
A 13C{1H} NMR spectrum of complex 19 was obtained (Figure 2.13), and displayed all of the 
expected peaks. In the 13C spectrum, the carbonyl carbons are observed as two singlets at 
218.72 ppm and 218.15 ppm. This is due to the local symmetry around the metal centre, in 
which the two carbonyl trans to the bipyridyl moiety are equivalent, and the carbonyl trans to 
the picolylamine nitrogen is in a different magnetic environment. These, as well as the proton 
peaks, were assigned using HSQC and COSY 2-D NMR spectroscopy experiments. 
The presence of the hexafluorophosphate anion was confirmed with 31P{1H} NMR, which 
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Figure 2.14: Assigned 1H NMR spectrum of complex 20 
 
Figure 2.14 displays the assigned 1H NMR spectrum of Mn(I) [2 + 1] complex 20. The peaks 
for the 2,2’-bipyridyl and the picolylamine moiety of the ligand are present in the correct ratios, 
which is shown by the correct integration of the peaks. It is clear from the small doublet 
observed at approx. 7.23 ppm that unreacted ligand is present. It is likely that there is a mixture 
of mono-, di- and tri-functionalised ligand. Due to this, the peak corresponding to proton Hd 
appears as a series of singlets, rather than a single singlet. This is observed in the analogous 
tris Re(I) complex (Figure 2.7, Section 2.3.1), and could indicate that, as well as not being 
fully functionalised, the molecule has restricted movement around single bonds in the ligand 
core, bringing about different magnetic environments for the same proton. This is evidenced 
by the HSQC experiment, which displays multiple crosspeaks for the singlets attributed to Hd, 
which all correspond to a single peak in the carbon spectrum. 
The aromatic carbon peaks in the 13C{1H} NMR spectrum for complex 20 are displayed in the 
region of 124 – 157 ppm. There is no peak in the 13C{1H} spectrum attributed to carbon Cf, but 
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The presence of a heptet (J = 708.7 Hz) at -144.13 ppm in the 31P NMR spectrum confirms the 
presence of the PF6 anions. 
 
Figure 2.15: Assigned 1H NMR spectrum of complex 21 
 
Figure 2.15 shows the 1H NMR spectrum of the tetranuclear Mn(I) [2 + 1] complex. The 
aromatic proton peaks arise in the same region as for Mn(I) complexes 19 and 20. Protons Hl-
Ho of the bipyridyl moiety are observed as multiplets in the aromatic region. The peak 
attributed to Hm overlaps with proton peak Ha to form an overlapping multiplet at 8.28 – 8.42 
ppm. The diagnostic peak attributed to methylene protons Hd appear as a doublet at 3.76 ppm. 
The doublet is formed from the coupling of Hd to protons Hb, with a coupling constant of 3.3 
Hz. The coupling was confirmed using a 2-D COSY NMR experiment. The aliphatic proton 
peaks attributed to the DAB-G1 core appear in the expected regions, and integrate for the 
expected number of protons. 
The presence of the PF6 anion was confirmed using a 31P{1H} NMR experiment, which resulted 
in a heptet at -144.13 ppm (J = 708.7 Hz). 
o l b n 
m/a 
d 
f i g/j h 
acetone-d6 
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In the 13C{1H} spectrum, the carbonyl carbons are observed as two singlets at 218.98 ppm and 
219.65 ppm, due to the symmetry discussed earlier. The aromatic carbon signals appear from 
124 – 156 ppm, and the aliphatic carbon signals, attributed to carbon Cd and the carbons in the 
DAB scaffold are in the range of 21 – 55 ppm. 2-D NMR experiments, namely COSY and 
HSQC, were used to assign the peaks in the proton and carbon spectra. 
2.5.2 Infrared Spectroscopy 
Fourier transform infrared spectroscopy experiments were used in combination with the other 
techniques to confirm the formation of the desired products. The characteristic carbonyl 
stretching bands are observed in the expected region, from 1900 – 2050 cm-1, confirming that 
complexation has occurred. Furthermore, a shift to higher wavenumbers in the C=N stretching 
band of the picolyl moiety from approximately 1600 cm-1 in the ligands to 1619 – 1622 cm-1 
upon complexation due to the back-bonding mentioned in Section 2.3.1 and Section 2.3.2 
confirms complexation via the pyridyl nitrogen.16 Figure 2.16 displays the infrared traces of 
complexes 19 – 21. 
 







Chapter 2     Synthesis and Characterisation of Ligands and Complexes  P a g e  | 62 
 
2.5.3 Elemental Analysis and Mass Spectrometry 
Elemental analysis and HR-ESI mass spectrometry experiments were used to further confirm 
the structural integrity of the Mn(I) [2 + 1] complexes. The mass spectral data for the complexes 
is summarisked in Table 2.12. Elemental analysis results confirmed the presence of the desired 
products in high purity. The unusual fragmentation pattern observed for complex 22 is likely 
due to exposure to light, either during or before the mass spectrometry analysis, hence the loss 
of the carbonyls. 
Table 2.12: ESI mass spectrometry results for Mn(I) [2 + 1] complexes 
Compound m/z Fragment 
19 445.11 [M-PF6]+ 
20 434.06 [M-3PF6]3+ 
21 964.90 [M-8CO-2PF6]2+ 
2.6 Mn(I) Bidentate Complexes 
The complexation reaction was achieved by stirring the metal precursor and the appropriate 
ligand at the appropriate stoichiometric ratio in DCM at room temperature. The general scheme 
for the formation of the Mn(I) bidentate complexes is shown in Scheme 2.6. 
 
Scheme 2.6: Synthesis of Mn(I)(bpy) monodentate complexes 22, 23 and 24. 
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The Mn(I) bidentate tricarbonyl complexes were isolated in good yields as orange powders 
(Table 2.13). They are all air-stable, light sensitive powders, which are soluble in methanol, 
ethanol, DCM, chloroform and DMSO. 
Table 2.13: Physical appearance and yield for the bidentate Mn(I) tricarbonyl complexes 
Compound Physical Appearance Yield (%) 
22 Orange powder 76 
23 Light orange powder 65 
24 Light orange powder 71 
2.6.1 1H and 13C{1H} NMR Spectroscopy 
The proposed chelation of the pyridyl and secondary amino nitrogens to form the bidentate 
(N,N)-Mn(I) complexes was confirmed by 1H NMR spectroscopy. The 1H NMR spectra of 
Mn(I) bidentate complexes 22 – 24 were recorded in deuterated acetone, and display 
characteristic peaks due to complexation, most notably splitting of the diastereotopic 
methylene peaks closest to the secondary amine, due to the formation of a chiral centre on the 
Mn(I) centre. The 1H NMR spectrum for complex 22 is shown in Figure 2.17. 
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Complexation can be confirmed by the splitting of proton signal Hf into two doublet of 
doublets. This occurs because the bonding mode holds those two protons in magnetically non-
equivalent positions. Protons Hh have also split into two signals, showing that they too are held 
in magnetically non-equivalent positions. 
The 13C{1H} NMR spectrum displays all the expected peaks and was assigned using an HSQC 
NMR spectrum. 
 
Figure 2.18: Assigned 1H NMR spectrum for complex 23 
 
Figure 2.18 displays the assigned 1H NMR spectrum of the trimeric Mn(I) complex 23. The 
splitting of the proton signals Hf and Hh confirm coordination and formation of the five-
membered ring. In a similar manner to complex 22, the methylene protons Hf and Hh are held 
in magnetically non-equivalent environments. 
The 13C{1H} NMR spectrum for complex 23 displays all the expected peaks, but extra peaks 
are visible in the aliphatic region. This could be due to the strained nature of the trimeric core, 




f f’ h h’ 
i 
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Figure 2.19: Assigned 1H NMR spectrum for complex 24 
 
The assigned 1H NMR spectrum of the bidentate Mn(I) complex 24 is displayed in Figure 
2.19. The splitting of proton signals Hf and Hh into Hf, Hf’, Hh and Hh’ confirms coordination 
of the MnBr(CO)3 moiety. The butyl core and propyl chain proton signals are visible in the 
expected region with the anticipated integration. The peak for proton Hi is slightly overlapping 
with the acetone-d6 signal. 
The 13C{1H} NMR spectrum displays the desired peaks, which were assigned using HSQC 
NMR techniques. 
2.6.2 Infrared Spectroscopy 
Infrared technology was used in conjunction with the other spectroscopic techniques to confirm 
the presence of the desired product. Table 2.14 gives a summary of the significant absorption 
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Table 2.14: Important infrared absorption bands for the Mn(I) bidentate complexes 
Compound C=Naromatic (cm-1) CO (cm-1) 
22 1609 2013 / 1886 
23 1609 2020 / 1895 
24 1609 2020 / 1889 
2.6.3 Elemental Analysis and Mass Spectrometry 
ESI-mass spectrometry was used to confirm the presence of the desired complexes. The data 
are consistent with the proposed structures, and are summarised in Table 2.15. Elemental 
analysis was used to further confirm the structural integrity of the products in high purity. 
Table 2.15: ESI mass spectrometry data for Mn(I) bidentate complexes 
Complex m/z Fragment 
22 283.90 [M – 3CO]+ 
23 995.88 [M – Br]+ 
24 1472.97 [M – Br]+ 
2.6.4 Single-crystal X-Ray Crystallography 
The molecular structure of the monomeric model manganese complex 22 was determined by 
X-ray diffraction, the results of which are shown in Figure 2.19. The single crystal was 
obtained by evaporation of DCM. The data attained from the SCXRD was used to confirm that 
complexation did occur with the correct bonding mode, and that the carbonyls are in a facial 
arrangement around the manganese centre. The geometry around the Mn(I) centre is pseudo-
octahedral. 
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Figure 2.19: Molecular structure of Mn(I) complex 22 
 
Complex 22 crystallises in the centrosymmetric space group P 1  , with four formula units per 
cell (Z = 4). The asymmetric unit contains two independent molecules positioned 
centrosymmetrically. The molecular structure of complex 22 is represented in Figure 2.19 
together with the numbering scheme. Table 2.16 and Table 2.17 show the general X-ray 
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Table 2.16: X-ray diffraction data of complex 22 
Empirical formula C12H14BrMnN2O3 
Formula weight 369.10 
Crystal system Triclinic 
Space Group P -1 
a (Å) 7.5876(5) 
b (Å) 12.1743(8) 
c (Å) 17.2183(11) 
α (°) 73.9730(10) 
β (°) 87.105(2) 
γ (°) 72.0140(10) 
V (Å3) 1452.94(16) 
Dcalc(mg.cm-3) 1.687 
μ (mm-1) 3.662 
F(000) 736 
T (K) 173 
Crystal colour Orange 
θ range (°) 1.2 – 28.3 
Index ranges h = -10 to 10 
 k = -16 to 16 
 l = -22 to 22 
Reflections collected 30335 
Independent reflections 7243 
Rint 0.049 
R indices Rl = 0.0304, wR2 = 0.0647 
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Table 2.17: Selected bond lengths and bond angles for complex 22 
Selected bond angles Bond angle (°)  Selected bond lengths Bond length (Å) 
Br(1A)-Mn(1A)-
C(1A) 
84.68(8)  Mn(1A)-C(1A) 1.816(2) 
Br(1A)-Mn(1A)-
C(2A) 
175.80(8)  Mn(1A)-C(2A) 1.797(2) 
Br(1A)-Mn(1A)-
C(3A) 
89.06(8)  Mn(1A)-C(3A) 1.802(2) 
Br(1A)-Mn(1A)-
N(1A) 
87.90(6)  Mn(1A)-Br(1A) 2.5275(5) 
Br(1A)-Mn(1A)-
N(2A) 
87.24(6)  Mn(1A)-N(1A) 2.057(2) 
N(1A)-Mn(1A)-C(1A) 170.44(10)  Mn(1A)-N(2A) 2.098(2) 
N(2A)-Mn(1A)-C(3A) 173.13(10)  C(8A)-N(1A) 1.343(3) 
 Bite angle (°)  C(9A)-N(2A) 1.486(3) 
N(1A)-Mn(1A)-
N(2A) 
78.97(8)  C(10A)-N(2A) 1.496(3) 
 
The coordination of the ligand 13 to the Mn(I) centre via the two ligand nitrogen atoms (N(1A), 
N(2A)) form a five-membered ring. The three carbonyl ligands are coordinated in a facial 
arrangement around the Mn(I) atom, which, together with the bromide anion, form a distorted 
octahedral arrangement around the metal centre. The carbonyl trans angles (Br(1A)-Mn(1A)-
C(2A), N(1A)-Mn(1A)-C(1A), N(2A)-Mn(1A)-C(3A)) range from 170.44(10) – 175.80(8) °, 
which is a minor deviation from the perfect octahedral angle of 180.00 °. 
The Mn-C bond lengths range from 1.797(2) – 1.816(2) Å, which is comparable to literature 
reports. 18-20 17-19 The bond length for the carbonyl trans to the bromide anion is the shortest at 
1.797(2) Å. This is unexpected, as one would expect a lengthening of the M-CO bond for the 
carbonyl trans to the Br ligand, as observed in two complexes synthesised by Mascharak et 
al.21 This may mean that there are more subtle factors at play in this case. 
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2.7 Summary 
Two series of ligands (10 – 15), based on n-propyl amine, tris(2-aminoethyl)amine and DAB 
generation one scaffolds, functionalised with 2- and 4-picolyl groups, were designed, 
synthesised and characterised using a range of spectroscopic and analytical techniques, 
including 1H and 13C NMR spectroscopy, infrared spectroscopy and EI mass spectrometry. 
A new series of Re(I) (16 – 18) and Mn(I) (19 – 21) tricarbonyl complexes, based on the [2 + 
1] approach, were produced and characterised using NMR spectroscopy (1H, 13C, COSY, and 
HSQC), infrared spectroscopy, ESI mass spectrometry and elemental analysis, all of which 
correspond well with the proposed structures. A new series of bidentate Mn(I) tricarbonyl 
complexes (22 – 24) were synthesised and characterised using the same techniques mentioned 
above. 
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Chapter 3      Physicochemical, Radiolabelling and 
Biological Evaluations 
3.1 Introduction 
CO has been found to be an important signalling molecule in mammalian bodies and displays a 
wide range of protective properties, including antiinflammatory,1 antiproliferative2 and 
antiapoptotic effects.3, 4 Furthermore, several research groups have shown that CO displays 
antimalarial effects,5-7 via carboxylation of haem groups of cell-free haemoglobin.8-11 CO is toxic 
in even relatively low concentrations, due to its lack of specificity.12 It was suggested by Green et 
al., and is now generally accepted, that a useful manner in which to deliver CO with temporal and 
spatial accuracy, is to use CORMs.13 
Besides treatment, early diagnosis of solid tumours and bacterial infections is enormously 
beneficial. One way to achieve this, in a non-invasive manner, is by labelling a molecule with a 
radioactive isotope, so that the tumour or infection can be imaged. New radiopharmaceuticals are 
needed that aggregate in solid tumours and microbial infections for imaging of the tumour or 
infection. 
Manganese and rhenium carbonyl complexes have shown promise as potential anticancer agents, 
with many IC50 values in the low micromolar range against a variety of cell lines.14-22 Several 
research groups have revealed that using the [2 + 1] approach is a useful tool in the art of rational 
drug design. In particular, it has been shown that cationic bipyridyl Re(I) tricarbonyl complexes 
display great potential in the field of anticancer research.16, 23, 24 In contrast, very little effort has 
been made towards potential Mn(I) [2 + 1] complexes as potential drugs, and it is a worthwhile 
research path to follow. 
Despite the relative success of Group 7 organometallic complexes as potential antitumour, 
antifungal and antiparasitic drugs, very little research has been conducted towards testing these 
compounds for possible antiparasitic activity. With the rapid rise in drug resistance in both cancer 
and malaria, new drugs with novel mechanisms are needed. This chapter covers the photochemical 
Chapter 3     Physicochemical, Radiolabelling and Biological Evaluations  P a g e  | 73 
 
properties of the Mn(I) complexes, antiproliferative studies and antiplasmodial studies of the 
complexes, as well as a preliminary study involving the radiolabelling of ligand 10 with 99mTc. 
3.2 Photochemical Properties of Mn(I) Compounds 
Even though manganese tricarbonyl systems are known to release CO under light illumination, it 
is important to establish whether the compounds release CO, how much CO is released from the 
complex, and the stability of the complex in the dark. Hence, the CO-release properties of the 
Mn(I) tricarbonyl complexes 19 – 24 were evaluated. Complex 22 was used as a model complex, 
and its CO-release properties were assessed using infrared spectroscopy, UV/Vis spectroscopy, 
and a myoglobin assay. The CO-release properties of complexes 19, 20, 21, 23 and 24 were 
assessed using UV/Vis spectroscopy. 
3.2.1 Long-term Stability of Compounds 
Infrared absorption spectroscopy was used to detect the loss of CO from the compound by a 
decrease in intensity of the CO stretching bands. When compound 22, as a pure solid, is exposed 
to natural daylight for as little as 90 minutes, a distinct decrease in the intensity of the CO stretching 
bands is observed in the infrared spectrum (Figure 3.1). 
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Figure 3.1: Infrared spectrum of complex 22 for a freshly prepared sample (black) and after 
exposure to natural daylight for 30 minutes (red) and 90 minutes (blue). 
 
The decrease in intensity of the CO stretching bands between 2020 cm-1 and 1875 cm-1 is indicative 
of substantial changes in the structure of the metal-carbonyl group, and is the first indication that 
CO-release is occurring from the compound. Additionally, upon prolonged exposure to natural 
daylight, solutions of complexes 19 – 24 lose their orange colour and turn to brown with a dark 
brown precipitate. 
3.2.2 Electronic Absorption and CO-release 
The absorbance maxima of complexes 19 – 24 were determined in a solution comprised of DMSO 
and PBS buffer (pH 7.4) (5:95 % v/v). Complexes 19 – 21 display two broad bands at ~290 nm and 
~380 nm, assigned to the intraligand charge transfer (ILCT) and the metal to ligand charge transfer 
(MLCT) bands, respectively. Complexes 22 – 24 do not display a ILCT, and display a MLCT in a 
similar region to complexes 19 – 21 at ~370 nm. Assignments of the ILCT and MLCT bands were 
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Figure 3.2: Overlay of the electronic absorption spectra of Mn(I) complexes 19 – 24 in 
DMSO/PBS (5:95 % v/v) 
3.2.2.1 CO-release 
To gain understanding into the photo-induced CO-release and the dark stability of complexes 19 -
24, the complexes were incubated in a DMSO/PBS (5:95 % v/v) solution in the absence of light 
for 16 hours. The UV/Vis spectrum was recorded every 30 minutes during the stability study 
(Figure 3.2, black). All of the complexes showed good stability in the dark in the aqueous solution, 
with only insignificant changes in the UV/Vis spectra observed, likely due to precipitation of the 
complex. The complexes were then irradiated with a custom-made LED array at 365 nm, 
coincident with the MLCT absorption maxima of the complexes. Irradiation was halted every 
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Figure 3.3: UV/Vis spectral traces of tetranuclear complex 21 in DMSO/PBS (5:95 % v/v) during 
incubation in the dark (0 to 16 h, black), followed by photoactivation with an LED cluster at 365 
nm for 12 min (red). 
 
Figure 3.3 shows a relatively consistent spectrum in the dark, indicating dark stability, and a 
marked decrease in the MLCT band upon irradiation with the 365 nm LED cluster. This is 
indicative of CO-release, and can be visualised as the change in absorbance at 365 nm versus time 
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Figure 3.4: Plot of absorption at 365 nm with increasing incubation time in the dark (0 to 16 h, 
blue), followed by photoactivation with an LED array at 365 nm for 12 min (orange) for a 
solution of complex 21 in DMSO/PBS (5:95 % v/v), monitored by UV/Vis spectroscopy. 
 
All of the Mn(I) tricarbonyl complexes displayed similar trends, that is, good dark stability in a 
DMSO:PBS (pH 7.4) solution, and a prominent decrease in the MLCT band upon irradiation with 
the LED cluster. 
3.2.3 CO-release using Myoglobin Assay 
The amount and rate of CO released from compound 22 was studied using the standard myoglobin 
assay,13 with modifications suggested by Fairlamb et al.29 Although the myoglobin assay is not the 
only method established for quantifying the amount and rate of CO released from compounds, it 
is the most widely used. In this method, changes in the UV/Vis spectrum of myoglobin, an iron-
based oxygen-binding protein, are monitored as it is converted from deoxy-myoglobin (deoxy-
Mb) to carboxy-myoglobin (CO-Mb).13, 29, 30 The conversion occurs by release of CO from the 
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µMs-1),29 resulting in a drastic change in the Q-band region of the UV/Vis spectrum (Figure 3.5). 
This data can be used to quantify CO-release from a CORM. 
 
Figure 3.5: UV/Vis spectra of the conversion of deoxy-Mb (black) to CO-Mb (light blue) in a 
control experiment 
 
Figure 3.5 shows the change in the UV/Vis spectrum of myoglobin as it is converted from deoxy-
Mb to CO-Mb. Isosbestic points are observed at 510, 550, 570 and 585 nm, with the Q-band region 
lying between 510 nm and 585 nm. Deoxy-Mb has one absorption peak in the Q-band region at 
557 nm, whereas CO-Mb has two peaks, with maxima at 540 and 577 nm. By measuring the 
change of absorbance at 540 nm, and correcting for the potential change in absorbance of the 
compound vs. the photo-product by aligning the spectra to intersect at the isosbestic point at 510 
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The concentration of the deoxy-Mb stock solution is determined by using the known extinction 
coefficient at 557 nm (Ɛ557 = 13.8 mM-1cm-1), and the concentration of CO-Mb is determined using 
the known extinction coefficient at 540 nm (15.4 mM-1cm-1).29 Sodium dithionite is used as a 
reducing agent to reduce the inactive Fe3+ version of myoglobin, metmyoglobin (met-Mb), to 
deoxy-Mb. 
3.2.3.1 Dark Stability in Myoglobin Solution 
Preceding the irradiation experiments, the stability of complex 22 was monitored under the 
conditions of the myoglobin assay (10 µM complex 22, 60 µM myoglobin, sodium dithionite, 0.01 
PBS, pH 7.4), to determine whether CO-release would occur in the absence of light. Spectral 
changes were monitored at 540 nm and 577 nm for the formation of CO-Mb, and 557 for the 
formation of deoxy-Mb. 
 
Figure 3.6: Change of absorption at selected wavelengths with increasing time in the dark (0 to 
16 h) for a solution of complex 22 (10 µM) in 0.01 PBS at pH 7.4 in the presence of myoglobin 
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If no change is occurring in the absence of light, the absorbances at the afore-mentioned 
wavelengths should remain constant. No appreciable change in absorbance was observed at any of 
the measured wavelengths over a period of 16 hours in the dark (Figure 3.6). This indicates that 
no CO-release to myoglobin occurs in the dark over this period. 
3.2.3.2 CO-release in Myoglobin Solution 
For the CO-release studies of complex 22 using the myoglobin assay, an LED cluster of 
wavelength 365 nm was used. A solution of myoglobin in 0.01 M PBS (pH 7.4) buffer (950 µL) 
was degassed by bubbling with argon and reduced by addition of a microspatula of sodium 
dithionite, before addition of complex 22 in DMSO (50 µL). Irradiation was performed at 37 °C 
with stirring, in 1 – 5 minute intervals. 
Photoexcitation of the myoglobin solution containing complex 22 resulted in the formation of CO-
Mb, as seen by the increase in absorbance at 540 nm and 577 nm, and a decrease in absorbance at 
557 nm (Figure 3.7). 
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Figure 3.7: Change of UV/Vis spectrum in the Q-band region of myoglobin with increasing 
irradiation time at 365 nm for a solution of complex 22 (10 µM) in 0.01 PBS at pH 7.4 in the 
presence of myoglobin (60 µM) and sodium dithionite, monitored by UV/Vis spectroscopy. 
 
The concentration of CO-Mb in the solution was determined at each time point, generating a plot 
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Figure 3.8: Concentration of CO-Mb (µM) formed with increasing irradiation time at 365 nm 
for a solution of complex 22 (10 µM) in 0.01 PBS at pH 7.4 in the presence of myoglobin (60 
µM) and sodium dithionite as monitored by UV/Vis spectroscopy. 
 
Figure 3.8 shows that the concentration of CO-Mb plateaus at ca. 12.5 µM for a 10 µM solution 
of complex 22, indicating that, on average, approximately 1.25 molecules of CO are released per 
molecule of 22 (Table 3.1). While many Mn(I) tricarbonyl complexes release all three equivalents 
of CO upon exposure to light,31, 32 some Mn(I) tricarbonyl complexes release fewer equivalents of 
CO, such as the complex synthesised by Smith et al., which releases 1.51 equivalents per 
tricarbonyl.28 
Table 3.1: CO-release data for complex 22 
Compound 
Conc. of CO-Mb 
(µM) 
Eq. of CO released 
Percentage of CO 
released (%) 
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The equivalents and the percentage of CO released by complex 22 is comparable to similar 
complexes in literature.28 The rate of CO-release is given by a half-life (t1/2) value, defined as the 
time taken for the complex to release 50 % of the total CO-ligands released. To be used as an 
effective therapeutic agent, the t1/2 needs to be less than 2 hours to result in a high enough 
concentration of CO within the cell.33  
The CO-release t1/2 of complex 22 was determined by fitting a 1st order exponential growth curve 
to the CO-release profile of the complex (Figure 3.8). The data were fitted to a general equation 
for a 1st order exponential growth curve using data analysis and graphing software OriginPro.34 
The derivation of the t1/2 equation is shown below. 
𝑦 = 𝑦0 + 𝐴1𝑒
𝑥
𝑡1                                          𝐸𝑞𝑛. 3.1 
[𝑀𝑏𝐶𝑂] = 𝑦0 + 𝐴1𝑒
𝑡1/2





𝑡1 + 𝑦0                                    𝐸𝑞𝑛. 3.3 
𝑡1/2 = 𝑡1 ln (
−𝑦0
2𝐴1
)                                    𝐸𝑞𝑛. 3.4 
Equation 3.1 is the general equation for a 1st order exponential growth. Substituting the relevant 
values (y = [MbCO] and x = t1/2) affords Equation 3.2. y0 is the y-value at which the graph plateaus, 
so at t1/2 [MbCO] = y0/2, giving Equation 3.3. Rearrangement to make t1/2 the subject of the 
equation produces Equation 3.4. Values for the variables t1, A1 and y0 are given by fitting the curve 
in OriginPro, and are substituted into Equation 4 to reveal the t1/2 of the complex. 
The CO-release t1/2 of complex 22 was calculated to be 12.84 minutes, which is far below the 
threshold of 2 hours. The t1/2 that was obtained for complex 22 is comparable to many photo-
CORMs in literature.28, 35 It must be noted that the t1/2 is dependent on the intensity of the light 
source and the compound concentration in the assay. 
3.3 Antiproliferative Studies 
With the established tumour-inhibiting effects exhibited by rhenium16-19 and manganese14, 20, 21, 36 
complexes, and the current interest in metallodendrimers for biological applications, the in vitro 
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biological activity of the Re(I) complexes 16 – 18 was evaluated against epithelial carcinoma 
(A431), colon carcinoma (DLD-1) and ovarian carcinoma (A2780) cancer cell lines, in addition to 
normal fibroblast cells (BJ). The in vitro biological activity of Mn(I) complexes was evaluated 
against epithelial carcinoma (A431) and malignant melanoma (A375) cells. 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay 
was performed to generate a dose-response curve, from which IC50 values for the complexes 16 – 
24 (Figure 3.9) were obtained. The IC50 value is defined as half of the maximal inhibitory 
concentration of a potential drug, and is a measure of the effectiveness of a substance to inhibit, in 
this case, the functioning of a cell. In an MTT assay, the viable cells are able to catalyse the 
conversion of MTT (yellow) to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan (MTT-
formazan, purple) (Scheme 3.1) by means of NADH-dependent cellular oxidoreductase enzymes. 
Therefore, the lower the IC50 value, the more potent the compound is. 
 
Scheme 3.1: Reduction of MTT to MTT-formazan 
 
The change in colour is measured spectroscopically, and can be used to determine the viability of 
the cells in each well of the plate. From the spectroscopic measurements, a sigmoidal dose-
response curve is generated, and the IC50 value can be interpreted. No known anti-cancer drug was 
used as a control in the anti-proliferative studies. The dose-response curves obtained for complex 
18 against all four cell lines are shown in Figure 3.9. The IC50 results of the Re(I) complexes 16, 
17 and 18 and shown in Table 3.2. 
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Figure 3.9: Sigmoidal dose-response curve corresponding to complex 18. 
 
 
The tested complexes displayed moderate to good cytotoxicity against A2780, A431 and DLD-1 
tumour cells, and are toxic to some extent against the normal BJ cells. Complex 18 displays the 
best inhibitory effect against all of the tested cell lines. No selectivity is observed in the case of 
complex 16, as the IC50 values are similar against the tumour and non-tumourigenic cells. Some 
selectivity is observed for complexes 17 and 18, as significantly higher IC50 values are observed 
against the healthy BJ cell line, which indicates a lower toxicity towards normal human cells. 
No trend is observed regarding the number of metal centres present per molecule. Complex 18 is 
the most cytotoxic, followed by complex 16, while complex 17 is the least cytotoxic. 







A431 DLD-1 A2780 BJ 
16 [2 + 1] 1 57.84 ± 3.67 17.85 ± 1.79 26.61 ± 3.66 18.97 ± 1.76 
17 [2 + 1] 3 46.64 ± 21.89 15.04 ± 2.20 36.45 ± 3.54 58.82 ± 7.65 
18 [2 + 1] 4 14.09 ± 2.23 10.18 ± 0.47 6.38 ± 1.18 17.69 ± 1.50 
a number of metal centres per molecule 
b IC50 value ± standard error 
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The complexes display the most potent activity against the colon carcinoma cell line (DLD-1), and 
the least potent activity against the epithelial carcinoma cell line (A431). 
The in vitro cytotoxicity of Mn(I) complexes 19 – 24 was evaluated against epithelial carcinoma 
(A431) and malignant melanoma (A375) cell lines. The results are displayed in Table 3.3. 
 
The Mn(I) complexes displayed moderate to good cytotoxicity against the tested cell lines. [2 + 1] 
complex 21 displayed the most potent activity, with IC50 values < 10 µM. This is interesting, as 
complex 21 is the Mn(I) analogue of Re(I) complex 18, which displayed the best activity of the 
Re(I) complexes. With the exception of complex 24 against the A375 cell line, Mn(I) complexes 
with a nuclearity of four (n = 4) display the best activity. A trend is observed in the [2 + 1] Mn(I) 
complexes where an increase in nuclearity (n) leads to an increase in activity. This is not observed 
for the bidentate Mn(I) complexes, where complexes 22 and 24 display the most potent 
cytotoxicity, followed by complex 23. 
The [2 + 1] complexes display higher in vitro activity than their bidentate counterparts, with an 
overall average IC50 of 20.33 µM vs 31.82 µM. The complexes display higher cytotoxicity towards 
the epithelial carcinoma (A431) than the malignant melanoma (A375) cell line. The cytotoxicity 
of the Mn(I) complexes was not evaluated against healthy cells, so the selectivity could not be 
assessed. 







19 [2 + 1] 1 15.57 ± 2.40 65.30 ± 7.60 
20 [2 + 1] 3 14.92 ± 1.02 12.05 ± 1.72 
21 [2 + 1] 4 5.26 ± 0.74 8.85 ± 0.58 
22 Bidentate 1 25.16 ± 2.47 15.79 ± 1.90 
23 Bidentate 3 49.65 ± 8.06 57.59 ± 4.39 
24 Bidentate 4 11.23 ± 1.15 31.45 ± 3.54 
a number of metal centres per molecule 
b IC50 value ± standard error 
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Figure 3.10 shows the IC50 values of complexes 16 – 24 against all the tested cell lines. 
 
Figure 3.10: Comparison of IC50 values of complexes 16 – 24 against tumorous and healthy cells 
 
The only cell line that was used to evaluate the cytotoxicity of all the complexes was the epithelial 
carcinoma cell line (A431). Figure 3.11 shows a comparison of the IC50 values of complexes 16 
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Figure 3.11: Comparison of IC50 values of complexes 16 – 24 against A431 epithelial carcinoma 
cells 
 
While the Re(I) [2 + 1] complexes (16 – 18) and the Mn(I) bidentate complexes (22 – 24) display 
similar activity against the A431 cell line, the Mn(I) [2 + 1] complexes (19 – 21) display 
significantly higher activity. The Mn(I) [2 + 1] complexes display an increase of up to 3-fold 
compared to their counterparts in the other series. This is promising, as with the potent activity 
displayed by the Mn(I) [2 + 1] complexes, coupled with CO-release, could result in an extremely 
effective potential drug. 
An Alamar Blue assay was performed on the Re(I) complexes 16 – 18 to verify the results obtained 
using the MTT assay. The Alamar Blue assay tests the cells ability to reduce resazurin (blue) to 
resorufin (fluorescent pink). The intensity of the fluorescence is proportional to the number of cells 
with normal metabolic activity. The fluorescence is measured spectroscopically, and is a direct 
indicator of the proliferating, viable cells. Scheme 3.2 shows the reduction of resazurin to 
resorufin. 
Re [2 + 1]
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Figure 3.12: Influence of complex 18 on the cell proliferation in vitro. 
 
Figure 3.12 shows the decrease in fluorescence with an increase in concentration of complex 18. 
This is expected if the compound is stopping normal metabolic functioning of the cells, as less 
resorufin is produced, leading to a decrease in fluorescence. A deviation in the gradient of the slope 
from 0 negatively is an indication of the dose-dependency antiproliferative effect of the tested 
sample. Figure 3.12 shows that a negative slope is observed for all cell lines treated with 
compound 18. The same was observed for compound 16 against all cell lines. Compound 17 
displayed a negative slope against cell lines A2780 and DLD-1, but did not display a significant 
(95 % confidence interval) change in fluorescent intensity with an increase in concentration against 
A431 and BJ cell lines. 
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3.4 Antiplasmodial Studies 
Due to the lack of research into the antiplasmodial effects of Re(I) and Mn(I) tricarbonyl 
complexes, it was deemed worthwhile to evaluate the antiplasmodial activity of the synthesised 
compounds. Hence, complexes 16 – 24 were evaluated as potential antiplasmodial agents in vitro 
against both chloroquine-sensitive (NF54) and chloroquine-resistant (K1) strains of Plasmodium 
falciparum. The in vitro antiplasmodial assay was performed using a modified method described 
by Makler et al., using the parasite lactate dehydrogenase (pLDH) assay.37 Similarly to the MTT 
assay, the pLDH assay relies on the healthy parasite’s ability to reduce nitro blue tetrazolium 
(NBT) chloride to a formazan (NBT-formazan), resulting in a colour change (Scheme 3.3). 
 
 
Scheme 3.3: Reduction of NBT chloride to NBT-formazan 
 
The efficacy of the compounds was tested using the standard pLDH assay against both a 
chloroquine-sensitive strain and a chloroquine-resistant strain of P. falciparum (Section 3.4.1), 
and selected Mn(I) tricarbonyl complexes, known to release CO, were evaluated against a 






Chapter 3     Physicochemical, Radiolabelling and Biological Evaluations  P a g e  | 91 
 
3.4.1 Antiplasmodial Evaluation 
The samples were tested on one occasion in triplicate, and the data obtained from the in vitro 
antiplasmodial evaluation are shown in Table 3.4. 
Table 3.4: IC50 values of Re(I) and Mn(I) complexes 16 – 24 against CQ-sensitive (NF54) and 








16 Re [2 + 1] 1 3.29 ± 0.37 1.42 ± 0.08 0.432 
16b Re [2 + 1] 1 3.59 ± 0.45 2.49 ± 0.12 0.694 
17 Re [2 + 1] 3 3.45 ± 0.07 2.66 ± 0.12 0.771 
18 Re [2 + 1] 4 2.20 ± 0.13 1.37 ± 0.048 0.623 
19 Mn [2 + 1] 1 8.31 ± 1.25 2.22 ± 0.093 0.267 
20 Mn [2 + 1] 3 2.81 ± 0.74 1.02 ± 0.097 0.363 
21 Mn [2 + 1] 4 3.76 ± 0.40 0.99 ± 0.02 0.263 
22 Mn Bidentate 1 2.08 ± 0.12 1.98 ± 0.14 0.952 
23 Mn Bidentate 3 4.28 ± 0.51 1.68 ± 0.25 0.393 
24 Mn Bidentate 4 4.05 ± 0.054 1.59 ± 0.13 0.393 
CQ / / / 0.031 ± 0.010 0.30 ± 0.032 9.67 
a Number of metal centres per molecule 
b IC50 value ± standard error 
c Resistance index (IC50[CQ-resistant]/IC50[CQ-sensitive]) 
 
The complexes 16 – 24 display good activity against the NF54 and K1 strains of P. falciparum. 
The activities observed for these compounds are lower than that of chloroquine for both the CQ-
sensitive and the CQ-resistant strains. All of the IC50 values for the metal complexes are in the low 
micromolar range, although chloroquine is substantially more potent than any of the metal 
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complexes against both the NF54 and K1 strains of P. falciparum. The monomeric [2 + 1] Mn(I) 
complex 19 displayed the lowest activity in the NF54 strain, with an IC50 value of 8.31 µM. All of 
the other complexes displayed values in the range of 2 – 4.5 µM. The complexes all displayed 
similar IC50 values against the CQ-resistant strain of P. falciparum, in the range of 1 – 3 µM. This 
may mean that the complexes follow the same mechanism of action. 
Every complex displayed better activity in the CQ-resistant strain of P. falciparum, resulting in 
resistance indices of < 1. The compound with the best resistance index (RI) was complex 21, which 
displayed a resistance index of 0.263. This indicates that the compound is almost four times more 
efficacious against the CQ-resistant strain than the CQ-sensitive strain of P. falciparum. The 
bidentate Mn(I) tricarbonyl complex 22 displayed an RI of 0.952, indicating that the activity is 
almost equal in both of the strains. As expected, chloroquine displays a high RI of 9.67, indicating 
that it is much for efficacious against the CQ-sensitive strain than the CQ-resistant, suggesting 
resistance towards the drug. Since the complexes exhibit similar or higher activity in the K1 strain 
compared to the NF54 strain, this indicates that the complexes possibly act by a different 
mechanism of action to CQ, and overcome the resistance mechanism experienced by CQ. 
 
Figure 3.13: Comparison of IC50 values of complexes 16 – 24 against the NF54 strain of P. 
falciparum. 
Re [2 + 1]
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A general trend is observed with the Re(I) and Mn(I) [2 + 1] complexes, in which an increase in 
nuclearity (n) leads to an increase in efficacy in the NF54 strain of P. falciparum (Figure 3.13). 
This trend seems to reverse in the Mn(I) bidentate complexes, where the most active complex is 
the monomeric one (22). This trend is evident only against the NF54 strain, and is not observed 
against the K1 strain (Figure 3.14). No clear trend is observed for the efficacy of the complexes 
in the K1 strain. The Mn(I) bidentate complexes (22, 23, 24) all display similar activity in the K1 
strain, the Mn(I) [2 + 1] complexes (19, 20, 21) show an increase in activity with an increase in 
nuclearity, and the tris Re(I) complex (16) and the protonated monomeric complex (16b) have 
lower activities than both the monomeric and tetrameric analogues (17, 18). The complex 
displaying the best activity against the K1 strain is the tetrameric [2 + 1] Mn(I) complex 21. 
 
Figure 3.14: Comparison of IC50 values of complexes 16 – 24 against the K1 strain of P. 
falciparum. 
 
It is clear that the Mn(I) [2 + 1] series displays the highest efficacy against the K1 strain of P. 
falciparum, but the same cannot be said for the NF54 strain, against which the Re(I) series displays 
the highest efficacy. 
Re [2 + 1]
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With the exception of complex 19, the Re(I) and Mn(I) [2 + 1] complexes display similar activities 
against the NF54 strain of P. falciparum. The Mn(I) [2 + 1] complexes display better activity than 
the Re(I) analogues against the K1 strain. 
When comparing the [2 + 1] approach and the bidentate bonding modes of the Mn(I) complexes 
(19 – 21 vs. 22 – 24), it can be deduced that the [2 + 1] bonding mode shows slightly higher efficacy 
than the bidentate bonding mode against both NF54 and K1 strains. 
3.4.2 Antiplasmodial Evaluation with UV Irradiation 
To perform the in vitro antiplasmodial evaluation of Mn(I) complexes 19, 21, 22 and 24, two plates 
were set up simultaneously, a control plate (not irradiated) and an experiment plate (irradiated). 
The data for the experiment are shown in Table 3.5. 
Table 3.5: IC50 values of select Mn(I) complexes against CQ-resistant (K1) strain of P. 




19 6.04 ± 0.95 3.76 ± 0.69 
21 2.47 ± 0.11 1.46 ± 0.15 
22 2.22 ± 0.14 3.41 ± 0.40 
24 1.60 ± 0.29 3.132 ± 0.17 
CQ 0.13 ± 0.022 0.12 ± 0.012 
a Irradiated with 365 nm LED array for 15 minutes 
b IC50 value ± standard error 
 
The Mn(I) [2 + 1] complexes 19 and 21 show a distinct increase in efficacy against the K1 strain 
of P. falciparum upon irradiation, while the Mn(I) bidentate complexes 22 and 24 display a 
decrease in efficacy upon irradiation. The decrease in efficacy of complexes 22 and 24 upon 
irradiation is unexpected, as release of CO into the culture should decrease the viability of the 
parasites.38 This change in efficacy upon irradiation is displayed in Table 3.6 and Figure 3.15. 
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In Table 3.6, an IC50 ratio of 1 suggests that no change in efficacy occurs upon irradiation with 
the 365 nm LED cluster, a value of < 1 suggests an increase in activity upon irradiation, and a 
value of > 1 suggests that the efficacy of the compound decreases upon irradiation. Similar IC50 
ratios for complexes 19 and 21 of ca. 0.60 suggest that the activity of the complexes increases by 
almost a factor of 2 when irradiated. On the other hand, IC50 ratios of 1.54 and 1.96 for complexes 
22 and 24, respectively, suggest a notable decrease in efficacy upon irradiation. As expected, the 
IC50 ratio is close to 1 for chloroquine, as irradiation should have no effect on the efficacy of the 
drug. It is likely that the coordination mode of the complexes influences the rate and amount of 
CO released from the complexes. 
Table 3.6: Ratio of activity between dark and irradiated plates for complexes 19, 21, 22 and 24 
against K1 CQ-resistant P. falciparum. 
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Figure 3.15: Comparison of IC50 values showing changes in efficacy upon irradiation 
 
The standard antiplasmodial assay and the antiplasmodial assay with UV irradiation were 
performed on separate occasions, and a difference can be seen in the IC50 values of the tested 
compounds in the ‘K1’ column of Table 3.4 and the ‘Dark’ column of Table 3.5. Nonetheless, the 
results obtained are within the same range. 
The irradiation experiment could be improved upon significantly before confirming these 
preliminary results. Firstly, the LED array used for irradiation of the plates was not custom-made 
for 96-well plates, but was modified in-house from the original array used for the CO-release 
studies. It is therefore possible that there was uneven spread of irradiation, which may have 
affected the results that were obtained. 
A drastic improvement in activity against the K1 strain of P. falciparum is observed upon 
irradiation of complexes 19 and 21. This shows that CO-release using Mn(I) tricarbonyl 
complexes, in particular complexes with the [2 + 1] coordination mode, is a worthwhile avenue to 
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3.5 Preliminary Radiolabelling Studies 
Technetium-99m, a metastable, radioactive isotope of technetium, is a gamma-emitting 
radionuclide.39 It is the most widely used radionuclide, due to its suitable half-life of 6.02 hours, 
and gamma-energy of 140 keV.39, 40 The use of 99mTc allows for the real-time monitoring of organ 
function, diagnosis of medical conditions and follow-up disease progression using SPECT scans.41 
In this study, the radiolabelling of ligand 10 with 99mTc, to form an analogue of complex 16, is 
reported as a preliminary study into the radiolabelling of such [2 + 1] complexes. 
3.5.1 Formation of 99mTc(bpy)(CO)3 Species 
The formation of the 99mTc(bpy)(CO)3 species is achieved by heating a solution of pertechnetate 
(99mTcO4-) with various salts packaged as a pre-purchased kit (Isolink) to afford the tricarbonyl tri-
aqua 99mTc species, before the addition of excess 2,2’-bipyridyl and subsequent heating (Scheme 
3.4). The formation was monitored by HPLC coupled to a radiodetector. 
 
 
Scheme 3.4: Formation of Tc-bpy species 
 
Figure 3.16 shows the radiotrace of the tricarbonyl tri-aqua 99mTc species. The 99mTc-tricarbonyl 
aqua species displays a retention time of 1.59 minutes. The peak in the radiotrace at 2.50 minutes 
is residual pertechnetate. 
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Figure 3.16: HPLC radiotrace of 99mTc-tricarbonyl species 
 
The subsequent formation of the 99mTc(bpy)(CO)3 species is shown in Figure 3.17. The radiotrace 
peak attributed to the desired species has a retention time of 4.90 minutes. The other peaks which 
form during this transformation could not be identified. 
 
Figure 3.17: HPLC radiotrace of 99mTc(bpy)(CO)3 species 
 
With the formation of the 99mTc(bpy)(CO)3 species comes many peaks in the radio spectrum that 
cannot be identified. The peak that belongs to the desired species is believed to be the peak with 
the retention time of 4.90 min. The unidentified peaks could arise from substitution of the chloride 
ligand with H2O or CH3CN, which would change the retention time of the complex. 
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3.5.2 Radiolabelling of Ligand 10 
The desired transformation was achieved by adding the 99mTc(bpy)(CO)3 to a large excess of the 
monomeric ligand 10. The vial was then incubated at 40 °C for 20 minutes. A radiotrace of the 
crude product is shown in Figure 3.18. The peak with the retention time of 6.98 minutes is 
attributed to the desired radiolabelled product. 
 
 
Figure 3.18: HPLC trace of crude mixture after radiolabelling ligand 10 
 
The isolation of the radiolabelled ligand 10 was achieved by preparative HPLC, and the radiotrace 
is displayed in Figure 3.19. Unfortunately, the Re(I) ‘cold complex,’ 16 (retention time = 6.00 
min) did not match the retention time of the radiolabelled product (retention time = 6.98 min). The 
difference in retention time is likely due to the different counterions. The radiolabelled ligand 10 
has a chloride counterion due to the reaction being performed in a sodium chloride solution, 
whereas anion exchange was performed on the Re(I) analogue, complex 16, to form the PF6 adduct. 
A similar anion exchange was attempted by adding ammonium hexafluorophosphate to the NaCl 
solution, but the retention time of the radiolabelled product remained unchanged. This variance in 
retention time due to different counterions is a known phenomenon, as was shown by Hodges and 
co-workers in their work with synthetic peptides.42 The difference in retention times could also be 
due in part to the lag time between the radiodetector and the UV detector. 
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Figure 3.19: HPLC radiotrace of the radiolabelled ligand 10 
 
Radiolabelling of multimeric 4-picolylamine ligands was attempted, but were unsuccessful due to 
the large excess of ligand (> 300 times for monomeric ligand 10).  This large excess of ligand 
resulted in a mixture of mono-, di-, tri- and tetra-substituted radiolabelled ligands, and it was not 
deemed worthwhile to isolate the products. 
3.6 Overall Summary 
The Mn(I) tricarbonyl complexes (19 – 24) are stable in the absence of light for an extended period 
of time, however, exposure to natural daylight or upon photoactivation at 365 nm using an LED 
array, CO-release from the complexes occurs. This was shown using electronic absorption spectra 
of complexes 19 – 24, with the decrease in the MLCT absorption band indicating CO-release. 
Using complex 22 as a model, CO-release was confirmed using the standard myoglobin assay, 
monitored by UV/Vis absorption spectroscopy. Complex 22 was found to release 1.26 equivalents 
of CO per molecule of complex 22, with a half-life of 12.84 minutes. 
The in vitro anticancer activity of complexes 16 – 24 was studied using the MTT assay. Re(I) 
complexes 16 – 18 were evaluated against three cancerous cell lines (A431, DLD-1 and A2780) 
and one healthy cell line (BJ). Tetranuclear complex 18 displayed the most potent cytotoxicity, 
with IC50 values < 15 µM against all of the tested cancerous cell lines. Complexes 17 and 18 
displayed some selectivity towards the cancerous cell lines over the healthy cell line. An Alamar 
Blue assay was performed on the Re(I) complexes to verify the results obtained using the MTT 
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assay. Mn(I) complexes 19 – 24 were evaluated against two cancerous lines (A431 and A375). 
The complexes displayed moderate to good activity. Tetranuclear complex 21 displayed the best 
activity against both cell lines. The [2 + 1] Mn(I) complexes displayed increased activity compared 
to their bidentate counterparts. 
The in vitro antiplasmodial activity of complexes 16 – 24 was investigated using the pLDH assay 
against two strains of P. falciparum, a CQ-sensitive (NF54) and a CQ-resistant (K1) strain. The 
complexes displayed moderate to good efficacy against both strains, with IC50 values in the low 
micromolar range. All of the complexes displayed better activity against the CQ-resistant strain 
than the CQ-sensitive strain. Tetrameric complex 21 displayed the best activity against the CQ-
resistant strain, as well as the best selectivity towards the CQ-resistant strain over the CQ-sensitive 
strain, with an IC50 value of 0.99 µM and a resistance index of 0.263. 
The in vitro antiplasmodial activity of complexes 19, 21, 22 and 24 was investigated with 
irradiation with 365 nm light against the CQ-resistant strain of P. falciparum. Complexes 19 and 
21 displayed an almost two-fold increase in activity, while complexes 22 and 24 displayed a 
significant decrease in activity upon irradiation, suggesting that the [2 + 1] complexes are 
promising candidates and should be further investigated. 
Radiolabelling of ligand 10 with 99mTc was achieved to form a [2 + 1] complex by reacting ligand 
10 with 99mTc(bpy)(CO)3 to afford the desired product. The complex was isolated using preparative 
HPLC. Radiolabelling of ligands 11 and 12 were unsuccessful. 
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Chapter 4      Experimental Details 
4.1 General Details 
All reagents were purchased from Sigma-Aldrich and were used as received unless otherwise 
stated. Solvents were purchased from KIMIX and were used as received. Nuclear magnetic 
resonance (NMR) spectra were recorded on a Bruker Topspin GmbH (1H at 400.22 MHz, 13C{1H} 
at 100.65 MHz, 31P{1H} at 162.01 MHz) or a Varian Mercury 300 (1H at 300.08 MHz) 
spectrometer, with a Bruker Biospin GmbH casing and sample injector at 30 °C. Tetramethylsilane 
was used as the internal standard for the chemical shift reports. Infrared (IR) absorption spectra 
were recorded using a Perkin-Elmer Spectrum One FT-IR spectrometer using attenuated total 
reflectance (ATR). Mass spectrometry was carried out using a JEOL GC Mate II single magnetic 
mass spectrometer in the positive-ion mode. High resolution mass spectrometry was carried out 
using a Waters Synapt G2 ESI probe. Elemental analyses were carried out using a Fission EA 110 
CHNS analyser or an Elementar Vario EL Cube Analyser. Melting points were determined using 
a Buchi B-540 apparatus. Single-crystal X-ray diffraction data were collected on a Bruker KAPPA 
APEX II DUO diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). 
Data collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using the 
program SAINT.1 The data were scaled and absorption correction performed using SADABS.2 
The structure was solved by direct methods using SHELXS-972 and refined by full-matrix least-
squares methods based on F2 using SHELXL-20142 and using the graphics interface program X-
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4.2 Synthesis 
4.2.1 Synthesis of [MnBr(CO)5]5 (1) 
 
Bromine (0.262 g, 1.64 mmol) was added to a solution of dimanganese decacarbonyl (0.604 g, 
1.55 mmol) in hexane under an argon atmosphere. The mixture was stirred overnight, after which 
the solvent was removed by rotary evaporation to afford an orange powder. The crude product was 
dried in vacuo. The powder was then sublimed at 90 °C under reduced pressure to afford the 
product (1) as an orange powder. Yield: 0.693 g, 81 %. Melting point: 152 °C (decomposition). 
FTIR: v (cm-1) = 2036 (s, CO), 1982 (s, CO). Elemental analysis for MnBr(CO)5: Found C, 21.85 
%; calcd. C, 21.85 %. MS (EI, m/z): 273.81 (100 %, [M]+) 
4.2.2 Synthesis of [MnBr(bpy)(CO)3]6 (2) 
 
[MnBr(CO)5] (0.683 g, 2.48 mmol) and 2,2’-bipyridyl (0.395 g, 2.53 mmol) were refluxed at  
40 °C in Et2O (50 mL) for four hours. The solution was cooled in an ice bath, and the resulting 
powder (2) was filtered using a Hirsch funnel and washed with cold Et2O. Yield: 0.876 g, 94 %. 
Melting point: 209 °C (decomposition). 1H NMR (acetone-d6): δ (ppm) = 9.30 (d, 3J = 5.1 Hz, 
2H, Ha), 8.56 (d, 3J = 8.0 Hz, 2H, Hd), 8.21 (t, 3J = 7.6 Hz, 2H, Hc), 7.74 (t, 3J = 6.4 Hz, 2H, Hb). 
13C{1H} NMR (acetone-d6): δ (ppm) = 222.01 (CCO), 221.82 (CCO), 220.86 (CCO), 155.69 (Ce), 
153.84 (Ca), 138.34 (Cc), 126.35 (Cb), 122.40 (Cd). FTIR v (cm-1) = 2020 (s, CO), 1939 (s, CO), 
1909 (s, CO). Elemental analysis for MnBr(bpy)(CO)3: Found C, 41.69; H, 2.10; N, 6.90 %; 
calcd. C, 41.63; H, 2.15; N, 7.47 %. MS (EI, m/z): 156.03 (100 %, [M-3CO-Br-Mn]+), 289.87 
(99.5 %, [M-3CO]+), 375.85 (8.4 %, [M]+). 
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4.2.3 Synthesis of [Re(bpy)Cl(CO)3]7 (3) 
 
[ReCl(CO)5] (0.609 g, 1.68 mmol) and 2,2’-bipyridyl (0.263 g, 1.68 mmol) were refluxed in 
toluene (30 mL) for two hours. The crude product precipitated as a yellow powder, which was 
filtered and washed with n-pentane to afford the desired product (3) as a yellow powder. Yield: 
0.729 g, 94 %. Melting point: 325 – 328 °C (melt and decomposition). 1H NMR (acetone-d6): δ 
(ppm) = 9.13 (ddd, 3J = 5.5, 4J = 1.6, 5J = 0.8 Hz, 2H, Ha), 8.71 (dt, 3J = 8.2, 4J = 1.0 Hz, 2H, Hd), 
8.35 (ddd, 3J = 8.2, 3J = 7.7, 4J = 1.6 Hz, 2H, Hc), 7.81 (ddd, 3J = 7.6, 3J = 5.5, 4J = 1.3 Hz, 2H, 
Hb). 13C{1H} NMR (acetone-d6): δ (ppm) = 198.11 (CCO), 189.88 (CCO), 189.75 (CCO), 155.82 
(Ce), 153.00 (Ca), 139.85 (Cc), 127.52 (Cb), 123.99 (Cd). FTIR v (cm-1) = 2016 (s, CO), 1867 (br, 
CO). Elemental analysis for Re(bpy)Cl(CO)3: Found C, 33.77; H, 1.46; N, 5.68 %; calcd. C, 
33.81; H, 1.75; N, 6.07 %. MS (EI, m/z): 377.97 (100 %, [M - 3CO]+), 461.94 (44.2 %, [M]+). 
4.2.4 Synthesis of N-propyl-1-(pyridine-4-yl)methanimine8 (4) 
4-Pyridinecarboxaldehyde (1.05 g, 9.77 mmol) and n-propylamine (0.610 g, 10.3 mmol) were 
stirred at room temperature in DCM (50 mL) over anhydrous magnesium sulfate for 21 hours. The 
MgSO4 was removed by gravity filtration and the solvent was removed from the filtrate, resulting 
in the pure product (4) as a red oil. Yield: 1.27 g, 87 %. 1H NMR (acetone-d6): δ (ppm) = 8.66 
(dd, 3J = 4.4, 4J = 1.6 Hz, 2H, Ha), 8.36 (s, 1H, Hd), 7.67 (dd, 3J = 4.4, 4J = 1.6 Hz, 2H, Hb), 3.61 
(td, 3J = 6.8, 4J = 1.4 Hz, 2H, He), 1.70 (sext, 3J = 7.2 Hz, 2H, Hf), 0.94 (t, J = 7.4 Hz, 3H, Hg). 
13C{1H} NMR (CDCl3): δ (ppm) = 158.85 (Hd), 150.41 (Ha), 143.19 (Hc), 121.94 (Hb), 63.63 (He), 
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23.89 (Hf), 11.85 (Hg). FTIR: v (cm-1) = 1647 (s, C=Nimine), 1598 (s, C=Naromatic). MS (EI, m/z): 
148.08 (100 %, [M]+). 
4.2.5 Synthesis of tris(2-((pyridine-4-ylmethylene)amino)ethyl)amine9 (5) 
Tris-(2-aminoethyl)amine (0.111 g, 0.760 mmol) and 4-pyridinecarboxaldehyde (0.277 g, 2.58 
mmol) were dissolved in DCM (20 mL). Anhydrous magnesium sulfate was added and the mixture 
was stirred at room temperature for 49 hours. The magnesium sulfate was removed by gravity 
filtration and the solvent removed from the filtrate. The resultant residue was purified by low 
pressure azeotropic distillation at 40 °C, with the addition of toluene in 5 mL aliquots to afford the 
product (5) as a brown residue. Yield: 0.294 g, 94 %. 1H NMR (CDCl3): δ (ppm) = 8.63 (d, 
3J = 
5.9 Hz, 2H, Ha), 8.08 (s, 1H, Hd), 7.38 (d, 
3J = 5.9 Hz, 2H, Hb), 3.71 (t, 
3J = 5.9 Hz, 2H, He), 2.95 
(t, 3J = 6.2 Hz, 2H, Hf). 13C{1H} NMR (CDCl3): δ (ppm) = 158.85 (Hd), 150.41 (Ha), 143.19 (Hc), 
121.94 (Hb), 63.63 (He), 23.89 (Hf), 11.85 (Hg). FTIR: v (cm-1) = 1643 (s, C=Nimine), 1594 (s, 
C=Naromatic). MS (EI, m/z): 413.24 (35.4 %, [M]+). 
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4.2.6 Synthesis of N1,N1,N4,N4-tetrakis(3-((pyridine-4-ylmethylene)amino)propyl)butane-
1,4-diamine10 (6) 
DAB-G1 dendrimer (0.0853 g, 0.269 mmol) and 4-pyridinecarboxaldehyde (0.119 g, 1.11 mmol) 
were dissolved in toluene (30 mL) and stirred over anhydrous magnesium sulfate for 24 hours at 
room temperature. The magnesium sulfate was removed by gravity filtration and the solvent 
removed from the filtrate. The resultant residue was taken up in DCM (20 mL) and washed with 
distilled water (10 × 20 mL). The organic layer was dried with anhydrous magnesium sulfate, 
which was subsequently removed by gravity filtration. The solvent was removed from the filtrate 
to afford the product (6) as a light brown oil. Yield: 0.108 g, 59 %. 1H NMR (CDCl3): δ (ppm) = 
8.60 (dd, 3J = 4.4, 4J = 1.6 Hz, 8H, Ha), 8.16 (s, 4H, Hd), 7.47 (dd, 3J = 4.5, 4J = 1.6 Hz, 8H, Hb), 
3.59 (t, 3J = 6.9 Hz, 8H, He), 2.44 (m, 8H, Hg), 2.34 (s, 4H, Hh), 1.76 (m, 8H, Hf), 1.35 (m, 4H, 
Hi). 13C{1H} NMR (CDCl3): δ (ppm) = 158.94 (Cd), 150.31 (Ca), 142.97 Cc), 121.76 (Cb), 59.68 
(Ce), 54.05 (Ch), 51.60 (Cg), 28.25 (Cf), 25.24 (Ci). FTIR: v (cm-1) = 1645 (s, C=Nimine), 1596 (s, 
C=Naromatic). MS (EI, m/z): 672.38 (100 %, [M]+). 
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4.2.7 Synthesis of N-propyl-1-(pyridine-2-yl)methanimine 8 (7) 
 
2-Pyridinecarboxaldehyde (1.04 g, 9.76 mmol) and n-propylamine (0.606 g, 10.3 mmol) were 
stirred at room temperature in DCM (50 mL) over anhydrous magnesium sulfate for 21 hours. The 
MgSO4 was removed by gravity filtration and the solvent was removed from the filtrate, resulting 
in the pure product (7) as a dark brown oil. Yield: 1.02 g, 70 %. 1H NMR (acetone-d6): δ (ppm) = 
8.63 (ddd, 3J = 4.8, 4J = 1.7, 5J = 1.0 Hz, 1H, Ha), 8.35 (d, 4J = 0.5 Hz, 1H, Hf), 8.04 (dt, 3J = 7.9, 
4J = 1.1 Hz, 1H, Hd), 7.84 (dddd, 3J = 8.0, 3J = 7.5, 4J = 1.8, 5J = 0.7 Hz, 1H, Hc), 7.41 (ddd, 3J = 
7.5, 3J = 4.8, 4J = 1.3 Hz, 1H, Hb), 3.63 (td, 3J = 6.8, 4J = 1.4 Hz, 2H, Hg), 1.81 – 1.63 (m, 2H, Hh), 
0.97 (t, 3J = 7.4 Hz, 3H, Hi). 13C{1H} NMR (acetone-d6): δ (ppm) = 161.65 (Cf), 155.09 (Ce), 
149.30 (Ca), 136.32 (Cc), 124.60 (Cb), 120.28 (Cd), 62.66 (Cg), 23.76 (Ch), 11.16 (Ci). FTIR v (cm-
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4.2.8 Synthesis of tris(2-((pyridine-2-ylmethylene)amino)ethyl)amine9 (8) 
 
2-Pyridinecarboxaldehyde (0.955 g, 8.92 mmol) and tris(2-aminoethyl)amine (0.435 g, 2.97 
mmol) were dissolved in DCM (50 mL) and stirred over anhydrous magnesium sulfate for 24 
hours. The MgSO4 was removed by gravity filtration and the solvent removed from the filtrate to 
afford the crude product as a dark red residue. The residue was distilled under reduced pressure at 
60 °C, with the occasional addition of acetone (ca. 3 – 5 mL ) to aid in removal of the excess 
aldehyde, to afford the product (8) as a dark brown oil. Yield: 1.09 g, 89 %. 1H NMR (acetone-
d6): δ (ppm) = 8.61 (ddd, 3J = 4.8, 4J = 1.7, 5J = 1.0 Hz, 3H, Ha), 8.35 (d, 4J = 0.5 Hz, 3H, Hf), 8.01 
(dt, 3J = 7.9, 4J = 1.0 Hz, 3H, Hd), 7.85 – 7.73 (m, 3H, Hc), 7.38 (ddd, 3J = 7.5, 3J = 4.8, 4J = 1.2 
Hz, 3H, Hb), 3.80 (td, 3J = 6.5, 4J = 1.3 Hz, 6H, Hg), 3.02 (t, 3J = 6.5 Hz, 6H, Hh). 13C{1H} NMR 
(acetone-d6): δ (ppm) = 162.55 (Hf), 155.04 (He), 149.26 (Ha), 136.33 (Hc), 124.57 (Hb), 120.41 
(Hd), 59.84 (Hg), 55.39 (Hh). FTIR v (cm-1) = 1647 (s, C=Nimine), 1588 (s, C=Naromatic). 
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4.2.9 Synthesis of N1,N1,N4,N4-tetrakis(3-((pyridine-2-ylmethylene)amino)propyl)butane-
1,4-diamine11 (9) 
 
2-Pyridinecarboxaldehyde (0.693 g, 6.45 mmol) and DAB-G1 dendrimer (0.508 g, 1.60 mmol) 
were dissolved in dry DCM (30 mL) and stirred at room temperature over anhydrous magnesium 
sulfate for 24 hours. The MgSO4 was removed by gravity filtration and the solvent removed from 
the filtrate to afford the crude product as an orange residue. The residue was taken up in DCM (20 
mL) and washed with distilled water (8 × 20 mL). The organic layer was dried with anhydrous 
magnesium sulfate, which was subsequently removed by gravity filtration. The solvent was 
removed to afford the desired product (9) as an orange oil. Yield: 0.935 g, 87 %. 1H NMR (CDCl3): 
δ (ppm) = 8.61 (ddd, 3J = 4.9, 4J = 1.7, 5J = 1.0 Hz, 4H, Ha), 8.37 (d, 4J = 0.4 Hz, 4H, Hf), 7.95 (dt, 
3J = 7.9, 4J = 1.1 Hz, 4H, Hd), 7.74 – 7.65 (m, 4H, Hc), 7.27 (ddd, 3J = 7.5, 3J = 4.8, 4J = 1.2 Hz, 
4H, Hb), 3.68 (td, 3J = 6.9, 4J = 1.2 Hz, 8H, Hg), 2.58 – 2.49 (m, 8H, Hi), 2.47 – 2.37 (bm, J = 16.6 
Hz, 4H, Hj), 1.85 (quint, 3J = 7.1 Hz 8H, Hh), 1.47 – 1.37 (bm, 4H, Hk). 13C{1H} NMR (CDCl3): 
δ (ppm) = 162.02 (Cf), 154.71 (Ce), 149.52 (Ca), 136.60 (Cc), 124.67 (Cb), 121.33 (Cd), 59.69 (Cg), 
54.11 (Cj), 51.90 (Ci), 28.46 (Ch), 25.35 (Ck). FTIR v (cm-1) = 1647 (s, C=Nimine), 1586 (s, 
C=Naromatic). 
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4.2.10 Synthesis of N-(pyridin-4-ylmethyl)propan-1-amine (10) 
 
Ligand precursor 4 (1.02 g, 6.88 mmol) was stirred under argon in methanol (40 mL) in an ice 
bath in the presence of 3 Å molecular sieves. NaBH4 (1.05 g, 27.8 mmol) was added under argon 
and the ice removed. The mixture was stirred at room temperature for 22 hours. The reaction was 
quenched with cold distilled water (40 mL), and the solvent volume reduced to 30 mL. The product 
was extracted with DCM (40 mL), and the organic layer was washed with distilled water (2 × 20 
mL). The organic layer was then dried with MgSO4, which was removed by gravity filtration 
before removal of the solvent to afford the product (10) as a yellow oil. Yield: 0.781 g, 76 %. 1H 
NMR (acetone-d6): δ (ppm) = 8.49 (d, 3J = 5.5 Hz, 2H, Ha), 7.35 (d, 3J = 5.9 Hz, 2H, Hb), 3.80 (s, 
2H, Hd), 2.56 (t, 3J = 7.0 Hz, 2H, Hf), 1.52 (sext, 3J = 7.3 Hz, 2H, Hg), 0.93 (t, 3J = 7.4 Hz, 3H, 
Hh). 13C{1H} NMR (acetone-d6): δ (ppm) = 150.34 (Cc), 149.51 (Ca), 122.83 (Cb), 52.13 (Cd), 
51.03 (Cf), 22.94 (Cg), 11.15 (Ch). FTIR v (cm-1) = 3274 (br, NH), 1600 (s, C=Naromatic). MS (EI, 
m/z): 121.03 (100 %, [M-C2H5]+), 149.07 (45.3 %, [M-H]+). 
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4.2.11 Synthesis of tris(2-((pyridine-4-ylmethylene)imino)ethyl)amine (11) 
 
Ligand precursor 5 (1.06 g, 2.57 mmol) was stirred in methanol (30 mL) in an ice bath, under 
argon for ten minutes. NaBH4 (1.17 g, 30.8 mmol) was added and the ice bath removed. The 
mixture was stirred at room temperature for 24 hours. The reaction was quenched with cold 
distilled water (40 mL), and the solvent volume reduced to 30 mL. The product was extracted with 
DCM (40 mL), and the organic layer was washed with distilled water (2 × 20 mL). The organic 
layer was then dried with MgSO4, which was removed by gravity filtration before removal of the 
solvent to afford the product (11) as a brown oil. Yield: 0.932 g, 86 %. 1H NMR (acetone-d6): δ 
(ppm) = 8.45 (dd, 3J = 4.4, 4J = 1.6 Hz, 6H, Ha), 7.30 (dd, 3J = 5.3, 5J = 0.7 Hz, 6H, Hb), 3.79 (s, 
6H, Hd), 2.72 – 2.67 (m, 6H, Hf), 2.67 – 2.62 (m, 6H, Hg). 13C{1H} NMR (acetone-d6): δ (ppm) 
=149.57 (Ca), 123.58 (Cc) 122.93 (Cb), 54.00 (Cg), 51.93 (Cd), 46.96 (Cf). FTIR v (cm-1) = 3270 
(br, NH), 1600 (s, C=Naromatic). MS (EI, m/z): 298.16 (100 %, [M-C7H9N2]+), 419.26 (18.8 %, 
[M]+). 
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4.2.12 Synthesis of N1,N1,N4,N4-tetrakis(3-((pyridine-4-ylmethylene)amino)propyl)butane-
1,4-diamine (12) 
 
Ligand precursor 6 (0.063 g, 0.093 mmol) was stirred in methanol (30 mL) in an ice bath, under 
argon for ten minutes. NaBH4 (0.057 g, 1.51 mmol) was added and the ice bath removed. The 
mixture was stirred at room temperature for 22 hours. The reaction was quenched with cold 
distilled water (40 mL), and the solvent volume reduced to 30 mL. The product was extracted with 
DCM (40 mL), and the organic layer was washed with distilled water (2 × 20 mL). The organic 
layer was then dried with MgSO4, which was removed by gravity filtration before removal of the 
solvent to afford the product (12) as a brown oil. Yield: 0.0464 g, 72 %. 1H NMR (acetone-d6): δ 
(ppm) = 8.48 (dd, 3J = 4.4, 4J = 1.5 Hz, 8H, Ha), 7.33 (d, 3J = 5.9 Hz, 8H, Hb), 3.77 (s, 8H, Hd), 
2.63 (t, 3J = 6.7 Hz, 8H, Hf), 2.47 (t, 3J = 6.9 Hz, 8H, Hh), 2.38 (t, 3J = 5.7 Hz, 4H, Hi), 1.63 (p, 3J 
= 6.8 Hz, 8H, Hg), 1.50 – 1.39 (m, 4H, Hj). 13C{1H} NMR (acetone-d6): δ (ppm) = 150.35 (Cc), 
149.51 (Ca), 122.90 (Cb), 54.05 (Ci), 52.37 (Cd/h), 47.81 (Cf), 27.57 (Cg), 25.14 (Cj). FTIR v (cm-
1) = 3270 (br, NH), 1602 (s, C=Naromatic). Elemental analysis for C40H60N10·5H2O: Found C, 61.87 
%, H, 8.90 %, N, 18.23 %; calcd. C, 62.31 %, H, 9.15 %, N, 18.17 %.  MS (EI, m/z): 121.07 (100 
%, [M-C33H51N8]+), 149.05 (78.0 %, [M-C31H47N8]+). 
Chapter 4     Experimental Details   P a g e  | 116 
 
4.2.13 Synthesis of N-(pyridin-2-ylmethyl)propan-1-amine (13) 
 
Ligand precursor 7 (0.220 g, 1.49 mmol) was stirred under argon in methanol (10 mL) in an ice 
bath in the presence of 3 Å molecular sieves. NaBH4 (0.229 g, 6.05 mmol) was added under argon 
and the ice removed. The mixture was stirred at room temperature for 5 hours before gravity 
filtration and removal of the solvent. The resulting residue was taken up in DCM (20 mL) and 
washed with a saturated aqueous Na2CO3 solution (4 × 20 mL). The organic layer was dried with 
anhydrous sodium carbonate, which was subsequently removed by gravity filtration. The solvent 
was removed to afford the desired product (13) as a light brown oil. Yield: 0.0991 g, 44 %. 1H 
NMR (acetone-d6): δ (ppm) =8.50 (ddd, 3J = 4.8, 4J = 1.7, 5J = 0.9 Hz, 1H, Ha), 7.71 (qd, 3J = 7.6, 
4J = 1.8 Hz, 1H, Hd), 7.43 (dddd, 3J = 7.8, 4J = 1.6, 4J = 1.2, 5J = 0.6 Hz, 1H, Hc), 7.22 – 7.14 (m, 
1H, Hb), 3.84 (s, 2H, Hf), 2.60 – 2.55 (m, 2H, Hh), 1.59 – 1.42 (m, 2H, Hi), 0.93 (t, 3J = 7.4 Hz, 
3H, Hj). 13C{1H} NMR (acetone-d6): δ (ppm) = 161.05 (Ce), 148.90 (Ca), 136.01 (Cc), 121.65 (Cd), 
121.50 (Cb), 54.99 (Cf), 51.21 (Ch), 23.06 (Ci), 11.19 (Cj). FTIR v (cm-1) = 3290 (br, NH), 1592 
(s, C=Naromatic). MS (EI, m/z): 121.07 (100 %, [M-C2H5]+), 150.09 (28 %, [M]+). 
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4.2.14 Synthesis of tris(2-((pyridine-2-ylmethylene)imino)ethyl)amine (14) 
 
Ligand precursor 8 (1.09 g, 2.64 mmol) was stirred in methanol (30 mL) in an ice bath, under 
argon for ten minutes. NaBH4 (1.35 g, 35.7 mmol) was added and the ice bath removed. The 
mixture was stirred at room temperature for 24 hours. The reaction was quenched with cold 
distilled water (40 mL), and the solvent volume reduced to 30 mL. The product was extracted with 
DCM (40 mL), and the organic layer was washed with distilled water (2 × 20 mL). The organic 
layer was then dried with MgSO4, which was removed by gravity filtration before removal of the 
solvent to afford the product (14) as a brown oil. Yield: 0.775 g, 70 % 1H NMR (acetone-d6): δ 
(ppm) = 8.44 (d, 3J = 4.7 Hz, 3H, Ha), 7.65 (td, 3J = 7.6, 4J = 1.8 Hz, 3H, Hd), 7.42 (d, 3J = 7.8 Hz, 
3H, Hc), 7.20 – 7.12 (m, 3H, Hb), 3.86 (s, 6H, Hf), 2.83 – 2.52 (m, 12H, Hh/i). 13C{1H} NMR 
(acetone-d6): δ (ppm) = 160.63 (Ce), 148.89 (Ca), 136.06 (Cc), 121.76 (Cd), 121.52 (Cb), 54.78 (Cf), 
54.42 (Ch), 47.27 (Ci). FTIR v (cm-1) = 3292 (br, NH), 1591 (s, C=Naromatic). MS (EI, m/z): 419.90 
(100 %, [M]+). 
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4.2.15 Synthesis of N1,N1,N4,N4-tetrakis(3-((pyridine-2-ylmethylene)amino)propyl)butane-
1,4-diamine (15) 
 
Ligand precursor 9 (0.935 g, 1.39 mmol) was stirred in methanol (30 mL) in an ice bath, under 
argon for ten minutes. NaBH4 (0.856 g, 22.6 mmol) was added and the ice bath removed. The 
mixture was stirred at room temperature for 22 hours. The reaction was quenched with cold 
distilled water (40 mL), and the solvent volume reduced to 30 mL. The product was extracted with 
DCM (40 mL), and the organic layer was washed with distilled water (2 × 20 mL). The organic 
layer was then dried with MgSO4, which was removed by gravity filtration before removal of the 
solvent to yield compound 15 as a dark brown, viscous oil. Yield: 0.662 g, 70 %. 1H NMR 
(acetone-d6): δ (ppm) = 8.50 (dd, 3J = 4.0, 4J = 0.7 Hz, 4H, Ha), 7.70 (td, 3J = 7.7, 4J = 1.8 Hz, 4H, 
Hd), 7.42 (d, 3J = 7.8 Hz, 4H, Hc), 7.18 (dd, 3J = 6.9, 4J = 5.4 Hz, 4H, Hb), 3.84 (s, 8H, Hd), 2.66 
(t, 3J = 6.7 Hz, 8H, Hh), 2.48 (t, 3J = 6.9 Hz, 8H, Hj), 2.42 – 2.33 (m, 4H, Hk), 1.72 – 1.58 (m, 8H, 
Hi), 1.45 (s, 4H, Hl). 13C{1H} NMR (acetone-d6): δ (ppm) = 161.00 (Ce), 148.89 (Ca), 136.05 (Cc), 
121.74 (Cd), 121.51 (Cb), 55.13 (Cf), 54.10 (Ck), 52.36 (Ch), 47.79 (Cj), 27.75 (Ci), 25.13 (Cl). 
FTIR v (cm-1) = 3288 (br, NH), 1591 (s, C=Naromatic). MS (EI, m/z): 679.45. (100 %, [M-H]+). 
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4.2.16 Synthesis of [Re(bpy)(CO)3(10)]PF6 (16) 
 
[Re(bpy)Cl(CO)3] (0.105 g, 0.228 mmol) and silver triflate (0.075 g, 0.291 mmol) were stirred in 
DCM (30 mL) for 3 hours. The resulting precipitate (AgCl) was removed by gravity filtration. 
Ligand 10 was dissolved in DCM (5 mL) and added to the solution. The mixture was stirred at 
room temperature for 20 hours. Excess NH4PF6 was added to the solution, after which the solution 
was stirred for a further hour. Gravity filtration was employed to remove insoluble particles, and 
the solution was washed with distilled water (2×20 mL). The organic layer was dried with MgSO4, 
which was subsequently removed by gravity filtration, and the solvent removed. The remaining 
residue was dissolved in acetone (5 mL) and distilled water (10 mL) added to the solution. The 
solvent was reduced until it became cloudy, and placed in the fridge for 3 hours. The resulting 
precipitate was removed by gravity filtration and the product extracted from the aqueous solution 
with DCM (2×20 mL). The organic layer was dried with MgSO4, which was subsequently removed 
by gravity filtration. The solvent was removed, and the product dried in vacuo as an oily residue. 
Yield: 0.031 g, 19 %. Melting point: 104 – 107 °C. 1H NMR (acetone-d6): δ (ppm) = 9.49 (ddd, 
3J = 5.5, 4J = 1.4, 5J = 0.7 Hz, 2H, Hm), 8.77 (d, 3J = 8.2 Hz, 2H, Hj), 8.52 – 8.45 (m, 2H, Hk), 8.44 
(dd, 3J = 5.2, 4J = 1.4 Hz, 2H, Ha), 8.08 – 7.97 (m, 2H, Hl), 7.46 (d, 3J = 6.6 Hz, 2H, Hb), 3.80 (s, 
2H, Hd), 2.47 (t, 3J = 7.0 Hz, 2H, Hf), 1.51 – 1.36 (m, 2H, Hg), 0.86 (t, 3J = 7.4 Hz, 3H, Hh). 
13C{1H} NMR (acetone-d6): δ (ppm) = 195.68 (CCO), 191.71 (CCO), 156.21 (Ci), 155.89 (Cc), 
154.04 (Cm), 151.53 (Ca), 141.48 (Ck), 129.14 (Cl), 125.61 (Cb), 124.94 (Cj), 51.43 (Cd), 51.13 
(Cf), 22.80 (Cg), 11.02 (Ch). 31P{1H} NMR (acetone-d6): δ (ppm) = -144.30 (hept, J = 708.2 Hz) 
FTIR v (cm-1) = 2025 (s, CO), 1899 (br, CO), 1619 (s, C=Npyridyl) , 1604 (s, C=Nbpy). Elemental 
analysis for C22H22N4O3Re·PF6: Found C, 36.98, H, 3.02, N, 7.47 %; calcd. C, 36.62, H, 3.07, N, 
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7.76 %. MS (HR-ESI, m/z): 577.12 (100 %, [M-PF6]+, calcd. 577.12), 427.01 (33 %, [M-L1-PF6]+, 
calcd. 427.01). 
4.2.17 Synthesis of [Re(bpy)(CO)3(10)]PF6 (16b) 
 
[Re(bpy)Cl(CO)3] (0.0868 g, 0.188 mmol) and silver triflate (0.0613 g, 0.238 mmol) were stirred 
in methanol (15 mL) for two hours. The resulting precipitate (AgCl) was removed by gravity 
filtration. Ligand 10 (0.0338 g, 0.225 mmol) in methanol (20 mL) was added and the solution was 
refluxed under argon for 21 hours. An excess of aqueous NH4PF6 solution was added and the 
solution was stirred for a further five minutes. A black precipitate formed, which was removed by 
gravity filtration. Deionised water (10 mL) was added, and the solvent volume was reduced until 
a yellow precipitate formed. The solution was cooled on ice, and the precipitate was filtered on a 
Hirsch funnel. Yield: 0.0283 g, 18 %. 1H NMR (acetone-d6): δ = 9.55 – 9.44 (m, 2H, Hi), 8.80 – 
8.65 (m, 4H, Ha/l), 8.48 (td, J = 8.0, 1.5 Hz, 2H, Hk), 8.10 – 7.92 (m, 2H, Hj), 7.70 (dd, J = 5.3, 1.4 
Hz, 2H, Hb), 4.62 (s, 2H, Hd), 3.47 – 3.25 (m, 2H, Hf), 1.85 (dq, J = 15.0, 7.5 Hz, 2H, Hg), 0.99 (t, 
J = 7.5 Hz, 3H, Hh). 13C{1H} NMR (acetone-d6): δ = 196.49 (CCO), 195.34 (CCO), 191.50 (CCO), 
155.87 (Cl), 154.15 (Ch), 154.00 (Cc), 152.71 (Ca), 141.53 (Cj), 129.22 (Ci), 127.58 (Cb), 124.89 
(Ck), 50.66 (Ce), 49.78 (Cd), 19.46 (Cf), 10.08 (Cg). 31P{1H} NMR (acetone-d6): δ = -144.30 (hept, 
J = 708.2 Hz). FTIR v (cm-1) = 2028 (s, CO), 1915 (br, CO), 1625 (s, C=Npyridyl). Elemental 
analysis for C22H25N4O4Re·2(PF6)H2O: Found C, 30.06, H, 2.60, N, 5.82 %; calcd. C, 29.87, H, 
2.73, N, 6.33 %. MS (ES, m/z): 577.12 (100 %, [M]+). 
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4.2.18 Synthesis of [(Re(bpy)(CO)3)3(11)](PF6)3 (17) 
 
[Re(bpy)Cl(CO)3] (0.131 g, 0.284 mmol) and silver triflate (0.080 g, 0.311 mmol) were stirred at 
room temperature in DCM for 3 hours. The resulting precipitate (AgCl) was filtered and ligand 11 
(0.036 g, 0.0863 mmol) was added to the flask. The reaction mixture was stirred at room 
temperature for 19 hours, after which the solvent was removed and the resulting residue taken up 
in minimum ethanol (4 mL) and ammonium hexafluorophosphate (excess in H2O) was added to 
precipitate the crude product as a yellow powder. The powder was redissolved in minimum acetone 
and added dropwise to isopropanol (80 mL, 75 °C). The mixture was filtered through Celite while 
hot, and the product removed from the Celite by washing with DCM, before removal of the solvent 
to afford the product as a brown powder. Yield: 0.073 g, 12 %. Melting point: 145 – 150 °C. 1H 
NMR (acetone-d6): δ (ppm) = 9.44 (d, 3J = 5.6 Hz, 6H, Hl), 8.78 – 8.62 (m, 6H, Hi), 8.51 – 8.33 
(m, 12H, Hj/a), 8.07 – 7.91 (m, 6H, Hk), 7.41 (d, 3J = 6.5 Hz, 6H, Hb), 3.79 – 3.70 (m, 6H, Hd), 
3.33 – 3.23 (m, 6H, Hf), 2.94 – 2.79 (m, 6H, Hg). 13C{1H} NMR (acetone-d6): δ (ppm) = 195.52 
(CCO), 191.52 (CCO), 155.82 (Ch), 155.36 (Cc), 154.01 (Cl), 151.73 (Ca), 141.43 (Cj), 129.12 (Ck), 
125.90 (Cb), 124.84 (Ci), 53.06 (Cf), 50.37 (Cd), 42.17 (Cg). 31P{1H} NMR (acetone-d6): δ (ppm) 
= -144.26 (hept, J = 708.7 Hz). FTIR v (cm-1) = 2032 (s, CO), 1907 (s, CO), 1619 (s, C=Npyridyl) , 
1605 (s, C=Nbpy). MS (HR-ESI, m/z): 566.07 (15 %, [M-3PF6]3+, calcd. 566.10). Elemental 
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analysis for C63H57N13O9Re3·3PF6: Found C, 35.37, H, 2.89, N, 8.18 %; calcd. C, 35.46, H, 2.69, 
N, 8.35 %. 
4.2.19 Synthesis of [(Re(bpy)(CO)3)4(12)](PF6)4 (18) 
 
[Re(bpy)Cl(CO)3] (0.090 g, 0.194 mmol) and silver triflate (0.059 g, 0.229 mmol) were stirred in 
DCM (30 mL) for 3 hours. A precipitate (AgCl) was formed and removed by gravity filtration. 
Ligand 12 (0.033 mg, 0.0479 mmol) was dissolved in DCM (5 mL) and the solution added to the 
reaction mixture. The solution was stirred for 24 hours at room temperature, before the addition of 
NH4PF6 (excess) and subsequent stirring for one hour. The solvent was removed by rotary 
evaporation and the residue dissolved in minimum DCM. The solution was added to boiling 
isopropanol and stirred for five minutes. The solution was allowed to cool to room temperature, 
precipitating a brown powder. The powder was filtered using Celite and washed with isopropanol 
before being solubilised with DCM. The DCM was removed to afford the product as a brown 
powder. Yield: 0.061 g, 11 %. Melting point: 134 – 137 °C. 1H NMR (acetone-d6): δ = 9.47 (ddd, 
3J = 5.4, 4J = 1.4, 5J = 0.7 Hz, 8H, Ho), 8.74 (d, 3J = 8.1 Hz, 8H, Hl), 8.53 – 8.37 (m, 16H, Ha/m), 
7.99 (ddd, 3J = 7.6, 3J = 5.5, 4J = 1.2 Hz, 8H, Hn), 7.46 (d, 3J = 6.6 Hz, 8H, Hb), 3.83 (s, 8H, Hd), 
3.38 – 3.06 (m, 16H, Hf/h), 2.77 – 2.64 (m, 4H, Hi), 1.98 – 1.77 (m, 12H, Hg/j). 13C{1H} NMR 
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(acetone-d6): δ = 195.63 (CCO), 191.64 (CCO), 155.84 (Ck), 154.03 (Co), 151.71 (Ca), 151.66 (Cc), 
141.42 (Cm), 129.00 (Cn), 125.78 (Cb), 124.83 (Cl), 52.02 (Cf), 51.09 (Cd), 47.08 (Ch), 46.72 (Ci), 
23.87 (Cg), 23.72 (Cj). 31P{1H} NMR (acetone-d6): δ = -144.26 (hept, J = 708.9 Hz). FTIR v (cm-
1) = 2028 (s, CO), 1901 (s, CO), 1619 (s, C=Npyridyl), 1605 (s, C=Nbpy). MS (HR-ESI, m/z): 590.08 
(26 %, [M-CO-4PF6]4+), 547.05 (19 %, [M-7CO-4PF6]4+). Elemental analysis for 
C92H92N18O12Re4·4PF6·5H2O·2DCM: Found C, 35.28, H, 3.68, N, 7.26 %; calcd. C, 34.80, H, 
3.36, N, 7.77 %. 
4.2.20 Synthesis of [Mn(bpy)(CO)3(10)]PF6 (19) 
 
[Mn(bpy)Br(CO)3] (0.162 g, 0.433 mmol) and silver triflate (0.135 g, 0.525 mmol) were stirred in 
DCM (30 mL) for 3 hours. The resulting precipitate (AgBr) was removed by gravity filtration. 
Ligand 10 (0.079 g, 0.524 mmol) was dissolved in DCM (5 mL) and added to the solution. The 
mixture was stirred at room temperature for 20 hours. Excess NH4PF6 was added to the solution, 
after which the solution was stirred for a further hour. Gravity filtration was employed to remove 
insoluble particles, and the solution was washed with distilled water (2×20 mL). The organic layer 
was dried with MgSO4, which was subsequently removed by gravity filtration, and the solvent of 
the filtrate evaporated. The resulting residue was dissolved in minimum DCM and diethyl ether 
(ca. 8 mL) was added to form a residue. The solvent was discarded and the residue washed with 
diethyl ether and pentane to afford complex 19 as an oily yellow/orange residue. Yield: 0.169 g, 
66 %.  1H NMR (acetone-d6): δ = 9.58 (d, 3J = 5.2 Hz, 2H, Hm), 8.62 (d, 3J = 8.0 Hz, 2H, Hj), 8.37 
(td, 3J = 7.9, 4J = 1.5 Hz, 2H, Hk), 8.33 (d, 3J = 6.6 Hz, 2H, Ha), 7.99 (ddd, 3J = 7.6, 3J = 5.5, 4J = 
1.2 Hz, 2H, Hl), 7.40 (d, 3J = 6.0 Hz, 2H, Hb), 3.74 (s, 2H, Hd), 2.44 (t, 3J = 6.9 Hz, 2H, Hf), 1.50 
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– 1.32 (m, 2H, Hg), 0.83 (t, 3J = 7.4 Hz, 3H, Hh). 13C{1H} NMR (acetone-d6): δ = 218.72 (CCO), 
218.15 (CCO), 155.66 (Ci), 155.30 (Cc), 154.48 (Cm), 151.90 (Ca), 140.75 (Ck), 128.54 (Cl), 125.14 
(Cb), 123.95 (Cj), 51.29 (Cd), 51.07 (Cf), 22.79 (Cg), 11.06 (Ch). 31P{1H} NMR (acetone-d6): -
144.12 (hept, J = 708.4 Hz). FTIR v (cm-1) = 2025 (s, CO), 1899 (s, CO), 1619 (s, C=Npyridyl), 
1605 (s, C=Nbpy). MS (HR-ESI, m/z): 445.11 (67 %, [M-PF6]+, calcd. 445.11). Elemental 
Analysis for C22H22F6MnN4O3P: Found C, 44.51, H, 4.02, N, 9.36 %; calcd. C, 44.76, H, 3.76, N, 
9.49 %. 
4.2.21 Synthesis of [(Mn(bpy)(CO)3)3(11)](PF6)3 (20) 
 
[Mn(bpy)Br(CO)3] (0.159 g, 0.425 mmol) and silver triflate (0.140 g, 0.543 mmol) were stirred at 
room temperature in DCM (30 mL) for 3 hours. The resulting precipitate (AgBr) was removed by 
filtration and ligand 11 (0.054 g, 0.129 mmol) was added to the flask. The reaction mixture was 
stirred at room temperature for 19 hours, after which excess NH4PF6 was added to the reaction 
flask, followed by a further hour of stirring at room temperature. The mixture was filtered and 
washed with H2O (2 × 20 mL) and the organic layer was dried with MgSO4, which was 
subsequently removed by filtration. The solvent was removed by rotary evaporation. The resultant 
residue was dissolved in minimum DCM, which was added to boiling isopropanol (80 mL) with 
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stirring. The mixture was allowed to cool, and was filtered through Celite. The product was 
obtained by washing the Celite with DCM and removing the solvent to afford complex 20 as a 
pale-yellow powder. Yield: 0.052 g, 31 %. Melting point: 156 – 160 C (melt and decomposition). 
1H NMR (acetone-d6): δ (ppm) = 9.61 – 9.53 (m, 6H, Hl), 8.60 – 8.49 (m, 6H, Hi), 8.40 – 8.23 (m, 
12H, Hj/a), 8.00 – 7.87 (m, 6H, Hk), 7.34 (t, 3J = 6.0 Hz, 6H, Hb), 3.88 – 3.61 (m, 6H, Hd), 3.35 – 
3.12 (m, 6H, Hg), 3.08 – 2.83 (m, 6H, Hf). 13C{1H} NMR (acetone-d6): δ (ppm) = 156.59 (Cc), 
155.46 (Cl), 153.08 (Cj), 153.04 (Ch), 141.60 (Ca), 129.41 (Ck), 126.31 (Cb), 124.79 (Ci), 54.13 
(Cg), 51.20 (Cd), 44.09 (Cf). 31P{1H} NMR (acetone-d6): δ (ppm) = -144.13 (hept, J = 708.7 Hz). 
FTIR v (cm-1) = 2031 (s, CO), 1907 (s, CO), 1619 (s, C=Npyridyl), 1606 (s, C=Nbpy). MS (HR-ESI, 
m/z): 434.06 (21 %, [M-3PF6]3+calcd. 434.75). Elemental analysis for 
C63H57N13O9Mn3·3PF6·3H2O: Found C, 42.05, H, 3.70, N, 9.79 %; calcd. C, 42.18, H, 3.54, N, 
10.15 %. 
 
4.2.22 Synthesis of [(Mn(bpy)(CO)3)4(11)](PF6)4 (21) 
 
[Mn(bpy)Br(CO)3] (0.107 g, 0.286 mmol) and silver triflate (0.085 g, 0.331 mmol) were stirred at 
room temperature in DCM (30 mL) for 3 hours. The resulting precipitate (AgBr) was filtered off 
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and ligand 12 (0.044 g, 0.065 mmol) was added to the flask. The reaction mixture was stirred at 
room temperature for 19 hours, after which excess NH4PF6 was added to the reaction flask, 
followed by a further hour of stirring at room temperature. The mixture was filtered and washed 
with H2O (2 × 20 mL) and the organic layer was dried with MgSO4, which was subsequently 
removed by rotary evaporation. The resultant residue was dissolved in minimum DCM, which was 
added to boiling isopropanol (80 mL) with stirring. The mixture was allowed to cool, and was 
filtered through Celite. The product was obtained by washing the Celite with DCM and removing 
the solvent to afford complex 21 as a dull yellow powder. Yield: 0.049 g, 40 %. Melting point: 
156 – 159 C (melt and decomposition). 1H NMR (acetone-d6): δ = 9.64 – 9.50 (m, 8H, Ho), 8.65 
– 8.52 (m, 8H, Hl), 8.42 – 8.28 (m, 16H, Hm/a), 7.96 (dt, 3J = 6.4, 4J = 4.7 Hz, 8H, Hn), 7.35 (d, 3J 
= 4.6 Hz, 8H, Hb), 3.76 (d, 4J = 3.3 Hz, 8H, Hd), 3.37 – 3.22 (m, 8H, Hf), 3.22 – 3.11 (m, 8H, Hh), 
2.97 – 2.82 (s, 4H, Hi), 1.96 – 1.79 (m, 8H, Hg), 1.79 – 1.72 (m, 4H, Hj). 13C{1H} NMR (acetone-
d6): δ = 219.65 (CCO), 218.98 (CCO), 156.60 (CC), 155.44 (Co), 153.06 (Co), 153.02 (Cm), 141.62 
(Ca), 129.44 (Cn), 126.22 (Cb), 124.78 (Cl), 54.19 (Cf), 53.34 (Co), 52.97 (Ch), 51.83 (Cd), 48.30 
(Ci), 24.27 (Cg), 21.89 (Cj). 31P{1H} NMR (acetone-d6): δ = -144.13 (hept, J = 708.7 Hz). FTIR v 
(cm-1) = 2028 (s, CO), 1901 (s, CO), 1619 (s, C=Npyridyl), 1606 (s, C=Nbpy). MS (HR-ESI, m/z): 
964.90 (19.3 %, [M-8CO-2PF6]2+, calcd. 964.22). Elemental analysis for 
C92H92N18O12Mn4·4PF6·5H2O·DCM: Found C, 42.22, H, 4.28, N, 9.70 %; calcd. C, 42.69, H, 4.01, 
N, 9.64 %. 
4.2.23 Synthesis of [MnBr(CO)3(13)] (22) 
 
[MnBr(CO)5] (0.184 g, 0.670 mmol) and ligand 13 (0.104 g, 0.695 mmol) were stirred together in 
DCM (10 mL) for 23 hours. The solvent was  removed, and the residue dissolved in DCM (2 mL). 
Diethyl ether (10 mL) was added to precipitate the product. The product was filtered on a Hirsch 
funnel and washed with diethyl ether and n-pentane to yield the product (22) as an orange powder. 
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Yield: 0.188 g, 76 %. Melting point: 155 – 159 C (melt and decomposition).  1H NMR (acetone-
d6): δ = 8.98 (d, 3J = 5.4 Hz, 1H, Ha), 7.98 (td, 3J = 7.7, 4J = 1.5 Hz, 1H, Hc), 7.61 (d, 3J = 7.9 Hz, 
1H, Hd), 7.58 – 7.49 (m, 1H, Hb), 4.75 (dd, 2J = 15.7, 4J = 4.8 Hz, 1H, Hf), 4.21 (dd, 2J = 15.6, 3J 
= 10.8 Hz, 1H, Hf), 3.95 (s, 1H, Hg) 3.40 – 3.06 (m, 2H, Hh), 2.02 – 1.84 (m, 2H, Hi), 1.05 (t, 3J = 
7.4 Hz, 3H, Hj). 13C{1H} NMR (acetone-d6): δ = 222.50 (CCO), 221.94 (CCO), 221.76 (CCO), 160.24 
(Ce), 153.36 (Ca), 138.57 (Cd), 124.64 (Cb), 121.80 (Cc), 58.37 (Ch), 58.23 (Cf), 21.54 (Ci), 10.59 
(Cj). MS (HR-ESI, m/z): 367.92 (25.3 %, [M]+, calcd. 367.96), 283.96 (100 %, [M-3CO]+, calcd. 
283.97). Elemental analysis for C12H14BrMnN2O3: Found C, 39.16, H, 3.89, N, 7.15 %; calcd. C, 
39.05, H, 3.82, N, 7.59 %. 
 
4.2.24 Synthesis of [(MnBr(CO)3)3(14)] (23) 
 
[MnBr(CO)5] (0.093 g, 0.338 mmol) and ligand 14 (0.047 g, 0.113 mmol) were dissolved in DCM 
(30 mL). The mixture was stirred at room temperature for 19 hours. The solvent was removed by 
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rotary evaporation, and the resulting residue redissolved in DCM (1 mL). Addition of diethyl ether 
(8 mL) caused the precipitation of the product (23) as an orange solid. The solid was filtered on a 
Hirsch funnel and washed with diethyl ether and n-pentane. Yield: 0.079 g, 65 %. Melting point: 
216 C (decomposition). 1H NMR (acetone-d6): δ (ppm) = 9.00 – 8.82 (m, 3H, Ha), 8.06 – 7.78 
(m, 3H, Hc), 7.68 – 7.40 (m, 6H, Hb/d), 5.06 – 4.70 (m, 3H, Hf), 4.49 – 4.01 (m, 3H, Hf’), 3.88 – 
3.67 (m, 3H, Hh), 3.67 – 3.35 (m, 3H, Hh’), 3.35 – 3.03 (m, 6H, Hi). 13C{1H} NMR (acetone-d6): 
δ (ppm) =222.32 (CCO), 222.06 (CCO), 221.93 (CCO), 159.70 (Ce), 153.33 (Ca), 138.55 (Cd), 124.72 
(Cc), 121.81 (Cb), 58.67 (Cf), 54.35 (Ch), 52.85 (Ci). FTIR v (cm-1) = 2020 (s, CO), 1895 (br, CO), 
1609 (s, C=Naromatic). MS (HR-ESI, m/z): 995.88 (100 %, [M-Br]+, calcd. 995.88). Elemental 
analysis for C33H33Br3Mn3N7O9·0.5Et2O: Found C, 37.88, H, 3.68, N, 9.69 %; calcd. C, 38.34, H, 
3.53, N, 8.82 %. 
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4.2.25 Synthesis of [(MnBr(CO)3)4(15)] (24) 
 
[MnBr(CO)5] (0.229 g, 0.835 mmol) and ligand 15 (0.139 g, 0.204 mmol) were dissolved in DCM 
(30 mL). The mixture was stirred at room temperature for 19 hours. The solvent was removed by 
rotary evaporation, and the resulting residue redissolved in DCM (1 mL). Addition of diethyl ether 
(8 mL) caused the precipitation of the product (24) as an orange solid. The solid was filtered on a 
Hirsch funnel and washed with diethyl ether and n-pentane. Yield: 0.225 g, 71 %. Melting point: 
159 C (decomposition). 1H NMR (acetone-d6): δ (ppm) = 9.09 – 8.87 (m, 4H, Ha), 8.08 – 7.85 
(m, 4H, Hc), 7.68 – 7.33 (overlapping m, 8H, Hb/d), 4.80 (s, 4H, Hf), 4.21 (s, 4H. Hf’), 3.50 (s, 4H, 
Hh), 3.36 – 3.16 (m, 4H, Hh’), 2.91 – 2.46 (overlapping m, 12H, Hj/k), 2.33 – 2.14 (m, 4H, Hi), 1.62 
(s, 4H, Hl). 13C{1H} NMR (acetone-d6): δ (ppm) = 222.54 (CCO), 222.06 (CCO), 221.93 (CCO), 
160.32 (Ce) 153.31 (Ca), 138.55 (Cd), 124.60 (Cb), 121.80 (Cc), 58.30 (Cf), 55.71 (Ch), 53.70 (Ck), 
51.95 (Cj), 25.53 (Ci), 24.59 (Cl). FTIR v (cm-1) = 2020 (s, CO), 1889 (br, CO), 1609 (s, 
C=Naromatic). MS (HR-ESI, m/z): 1337.03 (79 %, [M-MnBr(CO)3+H]+, calcd. 1337.03), 1556.87 
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(63 %, [M+H]+, calcd. 1556.87). Elemental analysis for C52H60Br4Mn4N10O12·0.5n-pentane: 
Found C, 40.91, H, 4.49, N, 9.63 %; calcd. C, 40.70, H, 4.11, N, 8.79 %. 
4.3 Photochemical Studies 
Electronic spectra were recorded in a mixture of DMSO and 0.01 M PBS (pH 7.4) solution (5:95 
% v/v) using a Cary 60 UV/Vis spectrometer with a fibre optic dip probe attachment. Dark stability 
in DMSO/PBS solution was determined by taking a reading every 30 minutes for 16 hours, before 
irradiating the samples with 365 nm radiation using a custom-built LED array, measuring the 
electronic absorption spectrum every minute for 12 minutes. 
The myoglobin solution was prepared by sonicating ca. 30 mg of myoglobin from equine skeletal 
muscle (purchased from Sigma Aldrich) in 10.0 mL 0.01 M PBS solution. The concentration of 
the myoglobin was determined using a UV/Vis spectrum of the solution and the Beer-Lambert 
Law with the known extinction coefficient (13.8 mM-1cm-1 at 557 nm). A stock DMSO solution 
of the complex was prepared with a concentration of 2000 µM. The Fe3+ in myoglobin was reduced 
to Fe2+ by adding a microspatula of sodium dithionite. Complex stock solution and reduced 
myoglobin solution were added to the cuvette in volumes to make concentration of 10 µM complex 
and 60 µM myoglobin, made up to 1.0 mL with 0.01 mL PBS solution. The solution was then 
degassed with Ar. A t = 0 spectrum was recorded, and the cuvette was irradiated with a custom-
built 365 nm LED array for an hour. Irradiation was interrupted to record the UV/Vis spectra every 
minute for the first 10 minutes, every 2 minutes from 10 – 20 minutes, and every 5 minutes 
thereafter. 
4.4 Antiproliferative Studies 
All of the cancerous cell lines were acquired from the European Collection of Authenticated Cell 
Cultures through Sigma Aldrich. The normal human fibroblast cell line (BJ) was acquired from 
the American Type Culture Collection. The cells were cultured under conditions recommended by 
the cell bank using cell culture media and supplements from Sigma Aldrich. The cells were seeded 
on 96-well Nunclon Delta surface assay plates in wells containing 200 µL cell suspension. The 
compounds were diluted in DMSO, and serial dilutions were prepared using 0.01 M PBS solution, 
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to obtain concentrations in the range of 10 – 2500 µM. Each well containing cells was treated with 
the respective compound in a proportion of 1:20 (compound:cell culture media), to obtain a final 
concentration range of 0.5 – 125 µM of the compound in the cell culture media. The cells were 
subjected to the treatment for 24 hours. Untreated cells were used as a reference, and cell culture 
media without cells was used as a blank. Three independent experiments were performed, each in 
duplicate. The MTT reagent and the Hank’s media to dissolve the salt (5 mn/mL final 
concentration) were purchased from Sigma Aldrich. Measurements were made at 492 nm and 570 
nm using a Synergy 2.0 microplate reader, and the absorbance data were implemented using 
GraphPad Prism 5 software to obtain the sigmoidal curves and the IC50 values. 
The Alamar Blue dye was purchased from Thermo Fisher Scientific. The plates were loaded with 
cells and incubated and treated in the same way as for the MTT assay. After 24 hours of incubation, 
40 µL of dye was added to each sample, and the plate was incubated for three hours. The 
fluorescence of each well was measured using an excitation wavelength of 540 nm and was 
measured at 620 nm using the Synergy 2.0 microplate reader. 
4.5 Antiplasmodial Studies 
The samples were evaluated in triplicate against CQ-sensitive (NF54) and CQ-resistant (K1) 
strains of Plasmodium falciparum. In vitro cultures of asexual erythrocyte stages of the parasite 
were sustained using a modified literature method.12 The lactate dehydrogenase assay was 
employed to evaluate the in vitro antiplasmodial activity of the sample.13 Stock solutions of 20 
mg/mL were prepared in DMSO. The stock solution was stored at -20 °C, and dilutions were 
prepared on the day of the experiment. Chloroquine was used as a reference drug for all 
experiments. A starting concentration of 10 000 ng/mL was used as a starting concentration, which 
was serially diluted in medium until a concentration of 2 ng/mL was obtained. The IC50 values 
were obtained using a sigmoidal dose-response curve generated using GraphPad Prism 4 software. 
Antiplasmodial activity with CO-release was determined by irradiating the 96-well plate for 15 
minutes with a custom-built LED array at the beginning of the incubation period with the potential 
drug. 
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4.6 Radiolabelling Studies 
The formation of the 99mTc-tricarbonyl species was performed using an Isolink Kit (2.9 mg sodium 
tetraborate decahydrate, 7.8 mg sodium carbonate, 9.0 mg potassium sodium tartrate tetrahydrate 
and 4.5 mg sodium boranocarbonate). 1 mL of aqueous pertechnetate solution (TcO4-) was added 
to the Isolink kit, which was subsequently heated to 100 °C for 20 min to form the 99mTc tricarbonyl 
aqua species. The solution is then added to excess 2,2’-bipyridyl (1 mg) and heated at 40°C for 30 
min to form the 99mTc(bpy)(CO)3 species. The contents of the vial containing the 99mTc(bpy)(CO)3 
species was added to excess of the ligand (ca. 300 mmol) and the vial incubated at 40 °C for 20 
minutes. 
Analytical HPLC was performed on an Agilent Series 1200 machine coupled to a diode array 
UV/Vis detector and a Gina Star, Raytest Gabi Gamma Detector Benzstrasse 4, D-75334 
Straubenhard radiodetector. A reverse phase Phenomenex Luna C-18 column was used with a flow 
rate of 1.5 mL/min. For the preparative HPLC, a preparative Phenomenex Luna C-18 column was 
used with a flow rate of 7.0 mL/min. The HPLC method begins with an isocratic mixture of 30 % 
acetonitrile in 0.1 M NH4OAc solution for 20 seconds. At 20 seconds, the % acetonitrile increases 
linearly to 90 % at 5.0 minutes and remains isocratic until 8 minutes, where it decreases back to 
30 %. HPLC-grade solvents were used. 
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Chapter 5      Overall Summary, Conclusions and Future 
Outlook 
5.1 Summary and Conclusions 
The aim of this study was to: 
• design and prepare various mono- and multimeric group 7 tricarbonyl complexes, 
• evaluate them as antiproliferative and antiplasmodial agents, and  
• assess their CO-releasing properties and radiolabelled properties. 
Specifically, three scaffolds, a mono-, tris- and tetrameric scaffold were functionalised with 2- and 
4-picolyl entities to afford two series of ligands. The 2-picolylamine ligands were functionalised 
with an Mn(I) tricarbonyl entity, which bonded in an (N,N)-bidentate coordination mode. The 4-
picolylamine ligands were functionalised with Mn(I) and Re(I) bipyridyl tricarbonyl moieties, 
following the [2 + 1] approach. The complexes that are reported herein have been characterised 
using an array of spectroscopic and analytical techniques, and have been synthesised for the first 
time to the best of our knowledge. 
The ligands were prepared via Schiff base condensation reaction between either 2- or 4-
pyridinecarboxaldehyde and the appropriate dendritic amine. Characterisation of these ligands 
confirmed the presence of the proposed compounds in high purity. The [M(bpy)(CO)3X] (X = 
halide) precursors (2 and 3) were formed by reaction of the appropriate metal precursor with 2,2’-
bipyridyl. The 4-picolylamine ligands (10 – 12) were reacted with [M(bpy)(CO)3X] in the presence 
of AgOTf as a halide abstractor to yield a series cationic of Re(I) (16 – 18) and Mn(I) (19 – 21) [2 
+ 1] complexes. The spectroscopic and analytical data showed that the bonding of the metal to the 
ligand was via the 4-pyridyl nitrogen, and in a [2 + 1] fashion. The shift of the C=N absorption 
band in the infrared spectrum to higher wavenumbers, in addition to the upfield shift of the proton 
peak (H – C – N – M) in the 1H NMR spectrum, is evidence that the complexation occurred via 
the pyridyl nitrogen. 
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The 2-picolylamine ligands (13 – 15) were reacted with metal precursor [MnBr(CO)5] to afford a 
series of neutral Mn(I) tricarbonyl complexes (22 – 24). Complexation and the bidentate (N,N) 
coordination mode was confirmed by splitting of the magnetically non-equivalent protons in 1H 
NMR spectrum of the complexes, which were not present in the pure ligand. 
The stability and CO-release properties of the Mn(I) tricarbonyl complexes (19 – 24) were 
evaluated using UV/Vis absorption spectroscopy. All of the complexes are stable in the absence 
of light for an extended period of time. CO-release is triggered by photoactivation using a 365 nm 
LED array, and is observed by the decrease in intensity of the MLCT absorption band in the 
electronic spectra of the complexes. Mononuclear complex 22 was used as a model, with which 
CO-release was confirmed using the standard myoglobin assay. 
The in vitro antiproliferative activity of the Re(I) and Mn(I) tricarbonyl complexes 16 – 24 was 
evaluated using the MTT assay. The Re(I) complexes 16 – 18 were evaluated against three 
cancerous cell lines (A431, DLD-1 and A2780) and one non-tumourigenic cell line (BJ). The most 
effective compound against these cell lines was complex 18, which displayed IC50 values of < 15 
µM against all tested cancerous cell lines. Selectivity towards the cancerous cell lines over the 
non-tumourigenic cell line was observed for both multinuclear complexes 17 and 18, while 
complex 16 displayed no selectivity. An Alamar Blue assay was performed to confirm the results 
obtained using the MTT assay. Mn(I) complexes 19 – 24 were evaluated against two cancerous 
cell lines, A431 and A375, using the MTT assay. Again, the tetranuclear complex (21) displayed 
the most potent activity against both tested cell lines. The complexes synthesised with the [2 + 1] 
approach (19 – 21) displayed increased activity over their bidentate equivalents (22 – 24). 
The in vitro antiplasmodial activity of complexes 16 – 24 was evaluated against CQ-sensitive 
(NF54) and CQ-resistant (K1) strains of P. falciparum using the pLDH assay. All of the complexes 
displayed good efficacy against both strains, with IC50 values in the low micromolar region. The 
most potent activity against the CQ-resistant strain was observed using tetranuclear complex 21. 
The in vitro antiplasmodial activity of Mn(I) complexes 19, 21, 22 and 24 was evaluated with 
irradiation of the 96-well plates with 365 nm light against the CQ-resistant strain of P. falciparum. 
[2 + 1] complexes 19 and 21 displayed an increase of activity upon irradiation, while bidentate 
complexes 22 and 24 displayed a notable decrease in activity upon irradiation. 
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Radiolabelling of ligand 10 with 99mTc was accomplished by reacting ligand 10 with 
99mTc(bpy)(C)O)3 to afford a [2 + 1] complex. The product was isolated using preparative HPLC. 
Radiolabelling of ligands 11 and 12 with 99mTc were unsuccessful. 
5.2 Future Outlook 
The results presented herein show that group 7 metallodendrimers display great promise in the 
field of therapeutic and diagnostic drug design. Improvements to the compounds may be brought 
about in various manners, including the synthesis of higher generation dendrimers. The increase 
in dendrimer generation allows for the exploitation of the EPR effect, increasing the selectivity of 
the potential drugs, as well as a likely increase in activity due to the number of metal centres. 
Another modification could be the use of a modified 2,2’-bipyridyl moiety in the [2 + 1] 
complexes. The introduction of water-solubilising groups, or the use of a simple molecule, such 
as a 2,2’-bipyridyldiol, as a co-ligand, would increase the solubility in aqueous media, allowing 
for an increase in bioavailability of the potential drug. 
In order to make a true comparison, the myoglobin assay should be used to fully characterise the 
CO-release properties of Mn(I) complexes. Antiproliferative activity should be determined for all 
of the Mn(I) complexes with 365 nm irradiation. Following in a similar vein, the antiplasmodial 
assays with irradiation should be repeated to confirm the results obtained. 
A structure-activity relationship study should be performed to rationalise any trend found in the 
biological studies. Other photophysical properties should be obtained for the complexes, such as 
quantum yield and steady state lifetime, to determine whether there is any correlation between 
these properties and the complexes resultant biological activities. 
Radiolabelling of the multimeric ligands should be performed using a protocol that allows for 
excess 99mTc, in order to fully functionalise the dendritic arms. Furthermore, the identity of the 
radiolabelled product form by the radiolabelling of ligand 10 should be confirmed using an HPLC 
trace of complex 16, rather than complex 16b, which was used. 
Mechanistic studies should be performed for both the antiproliferative and the antiplasmodial 
studies. For the antiproliferative studies, the use of knockout cell lines can be used to determine 
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which transport protein is being utilised to gain access to the cell, as well as apoptotic studies to 
determine the mechanism of action of the potential drug. With regard to the antiplasmodial 
mechanism, β-haematin studies should be performed in order to determine a possible mode of 
antiplasmodial action. 
 
